PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11301858-5	2001	Four major flavonoids from Scutellaria Root were found to show inhibitory activity on eotaxin production at a concentration of 10 micrograms/ml in the order of baicalein > oroxylin A > baicalin > skullcapflavon II.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	175-185	C-C motif chemokine ligand 11	Homo sapiens	86-93
11331078-1	2001	We previously reported that oroxylin A, a polyphenolic compound, was a potent inhibitor of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	nitric oxide synthase 2, inducible	Mus musculus	138-169
11331078-1	2001	We previously reported that oroxylin A, a polyphenolic compound, was a potent inhibitor of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	nitric oxide synthase 2, inducible	Mus musculus	171-175
11331078-1	2001	We previously reported that oroxylin A, a polyphenolic compound, was a potent inhibitor of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	prostaglandin-endoperoxide synthase 2	Mus musculus	181-197
11331078-1	2001	We previously reported that oroxylin A, a polyphenolic compound, was a potent inhibitor of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	prostaglandin-endoperoxide synthase 2	Mus musculus	199-204
34492273-0	2021	Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	76-81
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	nitric oxide synthase 2, inducible	Mus musculus	52-56
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	prostaglandin-endoperoxide synthase 2	Mus musculus	61-66
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	B cell leukemia/lymphoma 2	Mus musculus	109-114
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	nitric oxide synthase 2, inducible	Mus musculus	193-197
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	prostaglandin-endoperoxide synthase 2	Mus musculus	202-207
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	168-178	nitric oxide synthase 2, inducible	Mus musculus	52-56
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	168-178	B cell leukemia/lymphoma 2	Mus musculus	109-114
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	168-178	nitric oxide synthase 2, inducible	Mus musculus	193-197
10751555-9	2000	The inhibitory effects of oroxylin A on LPS-induced iNOS and COX-2 gene expression were also demonstrated in Bcl-2-overexpressing RAW264.7 macrophages, suggesting that oroxylin A inhibition of iNOS and COX-2 expression was not due to its antioxidant effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	168-178	prostaglandin-endoperoxide synthase 2	Mus musculus	202-207
10751555-11	2000	These results indicated that oroxylin A, an active component in Huang Qin, inhibited LPS-induced iNOS and COX-2 gene expression by blocking NF-kappaB activation, whereas emodin inhibition of LPS-induced iNOS expression may be mediated by a different transcription factor.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	nitric oxide synthase 2, inducible	Mus musculus	97-101
10751555-11	2000	These results indicated that oroxylin A, an active component in Huang Qin, inhibited LPS-induced iNOS and COX-2 gene expression by blocking NF-kappaB activation, whereas emodin inhibition of LPS-induced iNOS expression may be mediated by a different transcription factor.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	prostaglandin-endoperoxide synthase 2	Mus musculus	106-111
10751555-0	2000	Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	nitric oxide synthase 2, inducible	Mus musculus	52-56
10751555-0	2000	Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	61-66
10751555-6	2000	Furthermore, oroxylin A inhibited the expression of LPS-induced iNOS and COX-2 proteins and mRNAs without an appreciable cytotoxic effect on RAW264.7 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	nitric oxide synthase 2, inducible	Mus musculus	64-68
10751555-6	2000	Furthermore, oroxylin A inhibited the expression of LPS-induced iNOS and COX-2 proteins and mRNAs without an appreciable cytotoxic effect on RAW264.7 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	prostaglandin-endoperoxide synthase 2	Mus musculus	73-78
8470908-1	1993	A structure-activity study was carried out to determine the important regions of baicalein and oroxylin A, two flavones isolated from the Chinese herb Scutellariae radix, in inhibiting NAD(P)H:quinone acceptor oxidoreductase (EC 1.6.99.2; DT-diaphorase).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	95-105	NAD(P)H quinone dehydrogenase 1	Homo sapiens	239-252
34890308-10	2021	Importantly, a novel CDK9 inhibitor, oroxylin A (OA), from Scutellaria baicalensis was investigated, and it showed strong therapeutic potential against HCC and a striking capacity to overcome drug resistance by downregulating PINK1-PRKN-mediated mitophagy.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	37-47	cyclin dependent kinase 9	Homo sapiens	21-25
34890308-10	2021	Importantly, a novel CDK9 inhibitor, oroxylin A (OA), from Scutellaria baicalensis was investigated, and it showed strong therapeutic potential against HCC and a striking capacity to overcome drug resistance by downregulating PINK1-PRKN-mediated mitophagy.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	37-47	PTEN induced kinase 1	Homo sapiens	226-231
34890308-10	2021	Importantly, a novel CDK9 inhibitor, oroxylin A (OA), from Scutellaria baicalensis was investigated, and it showed strong therapeutic potential against HCC and a striking capacity to overcome drug resistance by downregulating PINK1-PRKN-mediated mitophagy.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	37-47	parkin RBR E3 ubiquitin protein ligase	Homo sapiens	232-236
34492273-0	2021	Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	98-104
34188177-0	2022	Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	21-31	cyclin dependent kinase 9	Homo sapiens	6-10
34188177-0	2022	Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	21-31	tumor protein p53	Homo sapiens	51-54
34188177-0	2022	Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	21-31	MDM2 proto-oncogene	Homo sapiens	134-138
34188177-0	2022	Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	21-31	sirtuin 1	Homo sapiens	143-148
34188177-9	2022	The effects of a novel CDK9 inhibitor named oroxylin A (OA) from Scutellaria baicalensis are explored, with the results indicating that OA shows moderate and controlled inhibition of CDK9 activity and expression, and stabilizes wt-p53 by inhibiting CDK9-regulated MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cyclin-dependent kinase 9 (CDC2-related kinase)	Mus musculus	23-27
34188177-9	2022	The effects of a novel CDK9 inhibitor named oroxylin A (OA) from Scutellaria baicalensis are explored, with the results indicating that OA shows moderate and controlled inhibition of CDK9 activity and expression, and stabilizes wt-p53 by inhibiting CDK9-regulated MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cyclin-dependent kinase 9 (CDC2-related kinase)	Mus musculus	183-187
34188177-9	2022	The effects of a novel CDK9 inhibitor named oroxylin A (OA) from Scutellaria baicalensis are explored, with the results indicating that OA shows moderate and controlled inhibition of CDK9 activity and expression, and stabilizes wt-p53 by inhibiting CDK9-regulated MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	transformation related protein 53, pseudogene	Mus musculus	231-234
34188177-9	2022	The effects of a novel CDK9 inhibitor named oroxylin A (OA) from Scutellaria baicalensis are explored, with the results indicating that OA shows moderate and controlled inhibition of CDK9 activity and expression, and stabilizes wt-p53 by inhibiting CDK9-regulated MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cyclin-dependent kinase 9 (CDC2-related kinase)	Mus musculus	249-253
34188177-9	2022	The effects of a novel CDK9 inhibitor named oroxylin A (OA) from Scutellaria baicalensis are explored, with the results indicating that OA shows moderate and controlled inhibition of CDK9 activity and expression, and stabilizes wt-p53 by inhibiting CDK9-regulated MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	transformed mouse 3T3 cell double minute 2	Mus musculus	264-268
34188177-9	2022	The effects of a novel CDK9 inhibitor named oroxylin A (OA) from Scutellaria baicalensis are explored, with the results indicating that OA shows moderate and controlled inhibition of CDK9 activity and expression, and stabilizes wt-p53 by inhibiting CDK9-regulated MDM2 and SIRT1 signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	sirtuin 1	Mus musculus	273-278
34117368-0	2022	Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	growth differentiation factor 15	Homo sapiens	80-85
34117368-2	2022	In the present study, we demonstrated that oroxylin A, a natural product extracted from Scutellaria radix, significantly inhibits transforming growth factor-beta1 (TGF-beta1)-induced epithelial-mesenchymal transition (EMT) and metastasis in HCC.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	transforming growth factor beta 1	Homo sapiens	130-162
34117368-2	2022	In the present study, we demonstrated that oroxylin A, a natural product extracted from Scutellaria radix, significantly inhibits transforming growth factor-beta1 (TGF-beta1)-induced epithelial-mesenchymal transition (EMT) and metastasis in HCC.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	transforming growth factor beta 1	Homo sapiens	164-173
34117368-3	2022	Oroxylin A blocked the TGF-beta1/Smad signaling via upregulating the non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	transforming growth factor beta 1	Homo sapiens	23-32
34117368-3	2022	Oroxylin A blocked the TGF-beta1/Smad signaling via upregulating the non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	growth differentiation factor 15	Homo sapiens	69-122
34117368-3	2022	Oroxylin A blocked the TGF-beta1/Smad signaling via upregulating the non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	growth differentiation factor 15	Homo sapiens	124-129
34117368-4	2022	Oroxylin A promoted NAG-1 transcription by regulating the acetylation of CCAAT/enhancer binding protein beta (C/EBPbeta), a transcription factor that binds to the NAG-1 promoter.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	growth differentiation factor 15	Homo sapiens	20-25
34117368-4	2022	Oroxylin A promoted NAG-1 transcription by regulating the acetylation of CCAAT/enhancer binding protein beta (C/EBPbeta), a transcription factor that binds to the NAG-1 promoter.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	CCAAT enhancer binding protein beta	Homo sapiens	73-108
34117368-4	2022	Oroxylin A promoted NAG-1 transcription by regulating the acetylation of CCAAT/enhancer binding protein beta (C/EBPbeta), a transcription factor that binds to the NAG-1 promoter.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	110-119
34117368-4	2022	Oroxylin A promoted NAG-1 transcription by regulating the acetylation of CCAAT/enhancer binding protein beta (C/EBPbeta), a transcription factor that binds to the NAG-1 promoter.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	growth differentiation factor 15	Homo sapiens	163-168
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	histone deacetylase 1	Homo sapiens	67-88
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	histone deacetylase 1	Homo sapiens	90-95
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	histone deacetylase 1	Homo sapiens	189-194
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	histone deacetylase 1	Homo sapiens	218-223
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	CCAAT enhancer binding protein alpha	Homo sapiens	250-259
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	growth differentiation factor 15	Homo sapiens	292-297
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	prostaglandin-endoperoxide synthase 2	Homo sapiens	166-171
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	caspase 3	Homo sapiens	173-178
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	tumor protein p53	Homo sapiens	180-184
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	interleukin 6	Homo sapiens	186-190
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	tumor necrosis factor	Homo sapiens	192-195
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	AKT serine/threonine kinase 1	Homo sapiens	201-205
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	AKT serine/threonine kinase 1	Homo sapiens	287-290
34149863-13	2021	SCDP key active ingredients are mainly quercetin, wogonin, baicalein, acacetin, oroxylin A, and beta-sitosterol, which function mainly by regulating targets, such as PTGS2, CASP3, TP53, IL-6, TNF, and AKT1, and are associated with multiple signaling pathways as pathways in cancer, PI3K-Akt signaling pathway, apoptosis, IL-17 signaling pathways.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	interleukin 17A	Homo sapiens	321-326
33680110-0	2021	Oroxylin A attenuates IL-1beta-induced inflammatory reaction via inhibiting the activation of the ERK and PI3K/AKT signaling pathways in osteoarthritis chondrocytes.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 1 alpha	Homo sapiens	22-30
33680110-0	2021	Oroxylin A attenuates IL-1beta-induced inflammatory reaction via inhibiting the activation of the ERK and PI3K/AKT signaling pathways in osteoarthritis chondrocytes.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen-activated protein kinase 1	Homo sapiens	98-101
33680110-0	2021	Oroxylin A attenuates IL-1beta-induced inflammatory reaction via inhibiting the activation of the ERK and PI3K/AKT signaling pathways in osteoarthritis chondrocytes.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	AKT serine/threonine kinase 1	Homo sapiens	111-114
33159144-0	2020	Oroxylin A alleviates immunoparalysis of CLP mice by degrading CHOP through interacting with FBXO15.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	DNA-damage inducible transcript 3	Mus musculus	63-67
33587321-7	2021	Oroxylin A exhibited an appreciable suppressive effect against the entrance of the SARS-CoV-2-spiked pseudotyped virus into ACE2 cells, which showed good binding to ACE2 as determined using SPR and CMC.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	angiotensin converting enzyme 2	Homo sapiens	124-128
33587321-7	2021	Oroxylin A exhibited an appreciable suppressive effect against the entrance of the SARS-CoV-2-spiked pseudotyped virus into ACE2 cells, which showed good binding to ACE2 as determined using SPR and CMC.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	angiotensin converting enzyme 2	Homo sapiens	165-169
33587321-8	2021	Oroxylin A was shown to be a potential candidate in the treatment for COVID-19 by virtue of its blocking the entrance of SARS-CoV-2 into ACE2 cells by specifically binding to the ACE2 receptor.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	angiotensin converting enzyme 2	Homo sapiens	137-141
33587321-8	2021	Oroxylin A was shown to be a potential candidate in the treatment for COVID-19 by virtue of its blocking the entrance of SARS-CoV-2 into ACE2 cells by specifically binding to the ACE2 receptor.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	angiotensin converting enzyme 2	Homo sapiens	179-183
33542782-0	2021	Protective Effects of Oroxylin A against Doxorubicin-Induced Cardiotoxicity via the Activation of Sirt1 in Mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	sirtuin 1	Mus musculus	98-103
33052070-6	2020	In addition, an immunoprecipitation assay demonstrated that OroA increased the binding activity of IRF2BP2 to the nuclear factor of activated T-cells 1 (NFAT1), causing inducible nitric oxide synthase to cause an inflammatory reaction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	60-64	interferon regulatory factor 2 binding protein 2	Mus musculus	99-106
33052070-6	2020	In addition, an immunoprecipitation assay demonstrated that OroA increased the binding activity of IRF2BP2 to the nuclear factor of activated T-cells 1 (NFAT1), causing inducible nitric oxide synthase to cause an inflammatory reaction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	60-64	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	114-151
33052070-6	2020	In addition, an immunoprecipitation assay demonstrated that OroA increased the binding activity of IRF2BP2 to the nuclear factor of activated T-cells 1 (NFAT1), causing inducible nitric oxide synthase to cause an inflammatory reaction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	60-64	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2	Mus musculus	153-158
33052070-6	2020	In addition, an immunoprecipitation assay demonstrated that OroA increased the binding activity of IRF2BP2 to the nuclear factor of activated T-cells 1 (NFAT1), causing inducible nitric oxide synthase to cause an inflammatory reaction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	60-64	nitric oxide synthase 2, inducible	Mus musculus	169-200
33159144-0	2020	Oroxylin A alleviates immunoparalysis of CLP mice by degrading CHOP through interacting with FBXO15.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	F-box protein 15	Mus musculus	93-99
33159144-6	2020	Oroxylin A induces the transcription of E3 ligase F-box only protein 15 gene (fbxo15), and activated FBXO15 protein binds to CHOP and further mediates the degradation of CHOP through the proteasome pathway, which eventually relieves the immunoparalysis of CLP mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	F-box protein 15	Mus musculus	78-84
33159144-6	2020	Oroxylin A induces the transcription of E3 ligase F-box only protein 15 gene (fbxo15), and activated FBXO15 protein binds to CHOP and further mediates the degradation of CHOP through the proteasome pathway, which eventually relieves the immunoparalysis of CLP mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	DNA-damage inducible transcript 3	Mus musculus	125-129
33159144-6	2020	Oroxylin A induces the transcription of E3 ligase F-box only protein 15 gene (fbxo15), and activated FBXO15 protein binds to CHOP and further mediates the degradation of CHOP through the proteasome pathway, which eventually relieves the immunoparalysis of CLP mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	DNA-damage inducible transcript 3	Mus musculus	170-174
33159144-7	2020	Taken together, these findings suggest oroxylin A relieves the immunoparalysis of CLP mice by degrading CHOP through interacting with FBXO15.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	DNA-damage inducible transcript 3	Mus musculus	104-108
33159144-7	2020	Taken together, these findings suggest oroxylin A relieves the immunoparalysis of CLP mice by degrading CHOP through interacting with FBXO15.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	F-box protein 15	Mus musculus	134-140
32918978-0	2020	Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	fibronectin 1	Homo sapiens	20-31
32978517-0	2020	Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	76-86
32978517-0	2020	Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	96-99
32978517-5	2020	Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites on XPC promoter which is important to hypoxia-induced XPC transcription.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	131-141
32978517-5	2020	Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites on XPC promoter which is important to hypoxia-induced XPC transcription.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	229-232
32978517-5	2020	Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites on XPC promoter which is important to hypoxia-induced XPC transcription.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	280-283
32978517-6	2020	Taken together, our findings not only demonstrate a crucial role of XPC dependent NER in hypoxia-induced cisplatin resistance, but also suggest a previously unrecognized tumor suppressive mechanism of Oroxylin A in NSCLC which through sensitization of cisplatin-mediated growth inhibition and apoptosis under hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	201-211	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	68-71
33147823-8	2020	Especially, oroxylin A was effective against both p65 and IkappaBalpha, while wogonin and baicalein were suppressed phospho-p65 and phospho-IkappaBalpha, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	synaptotagmin 1	Rattus norvegicus	50-53
33147823-8	2020	Especially, oroxylin A was effective against both p65 and IkappaBalpha, while wogonin and baicalein were suppressed phospho-p65 and phospho-IkappaBalpha, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	NFKB inhibitor alpha	Rattus norvegicus	58-70
32918978-0	2020	Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	92-97
32918978-0	2020	Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	AKT serine/threonine kinase 1	Homo sapiens	98-101
32918978-0	2020	Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	catenin beta 1	Homo sapiens	102-114
32918978-11	2020	Furthermore, our results revealed that Oroxylin A markedly inhibited the expression of IP3R1 and the activation of AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	87-92
32918978-11	2020	Furthermore, our results revealed that Oroxylin A markedly inhibited the expression of IP3R1 and the activation of AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	AKT serine/threonine kinase 1	Homo sapiens	115-118
32918978-11	2020	Furthermore, our results revealed that Oroxylin A markedly inhibited the expression of IP3R1 and the activation of AKT/beta-catenin pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	catenin beta 1	Homo sapiens	119-131
32918978-12	2020	SIGNIFICANCE: Oroxylin A could reverse the insensitivity of TMZ via suppressing IP3R1/AKT/beta-catenin pathway and it might be helpful for enhancing the anti-cancer effect of TMZ in glioma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	80-85
32918978-12	2020	SIGNIFICANCE: Oroxylin A could reverse the insensitivity of TMZ via suppressing IP3R1/AKT/beta-catenin pathway and it might be helpful for enhancing the anti-cancer effect of TMZ in glioma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	AKT serine/threonine kinase 1	Homo sapiens	86-89
32918978-12	2020	SIGNIFICANCE: Oroxylin A could reverse the insensitivity of TMZ via suppressing IP3R1/AKT/beta-catenin pathway and it might be helpful for enhancing the anti-cancer effect of TMZ in glioma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	catenin beta 1	Homo sapiens	90-102
32512269-7	2020	Here we further revealed that the inhibition of the PI3K/Akt/mTOR signaling was required for Oroxylin A to induce autophagy activation, which may be the underlying mechanism of the anti-inflammatory activity of Oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	93-103	thymoma viral proto-oncogene 1	Mus musculus	57-60
32492489-0	2020	Oroxylin A suppresses ACTN1 expression to inactivate cancer-associated fibroblasts and restrain breast cancer metastasis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	actinin, alpha 1	Mus musculus	22-27
33164356-4	2020	The results showed that adenosine, epigoitrin, chlorogenic acid, caffeic acid, cichoric acid, corynoline, baicalin, wogonoside, wogonin and oroxylin A had a certain regulatory effect on inflammatory factor tumor necrosis factor(TNF-alpha), interleukin(IL-1beta) and IL-6 at specific concentrations in a dose-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	140-150	tumor necrosis factor	Homo sapiens	206-227
33164356-4	2020	The results showed that adenosine, epigoitrin, chlorogenic acid, caffeic acid, cichoric acid, corynoline, baicalin, wogonoside, wogonin and oroxylin A had a certain regulatory effect on inflammatory factor tumor necrosis factor(TNF-alpha), interleukin(IL-1beta) and IL-6 at specific concentrations in a dose-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	140-150	tumor necrosis factor	Homo sapiens	228-237
33164356-4	2020	The results showed that adenosine, epigoitrin, chlorogenic acid, caffeic acid, cichoric acid, corynoline, baicalin, wogonoside, wogonin and oroxylin A had a certain regulatory effect on inflammatory factor tumor necrosis factor(TNF-alpha), interleukin(IL-1beta) and IL-6 at specific concentrations in a dose-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	140-150	interleukin 1 alpha	Homo sapiens	240-260
33164356-4	2020	The results showed that adenosine, epigoitrin, chlorogenic acid, caffeic acid, cichoric acid, corynoline, baicalin, wogonoside, wogonin and oroxylin A had a certain regulatory effect on inflammatory factor tumor necrosis factor(TNF-alpha), interleukin(IL-1beta) and IL-6 at specific concentrations in a dose-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	140-150	interleukin 6	Homo sapiens	266-270
32512269-0	2020	ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	72-82	thymoma viral proto-oncogene 1	Mus musculus	37-40
32512269-0	2020	ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	72-82	mechanistic target of rapamycin kinase	Mus musculus	41-45
32512269-7	2020	Here we further revealed that the inhibition of the PI3K/Akt/mTOR signaling was required for Oroxylin A to induce autophagy activation, which may be the underlying mechanism of the anti-inflammatory activity of Oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	93-103	mechanistic target of rapamycin kinase	Mus musculus	61-65
32512269-7	2020	Here we further revealed that the inhibition of the PI3K/Akt/mTOR signaling was required for Oroxylin A to induce autophagy activation, which may be the underlying mechanism of the anti-inflammatory activity of Oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	211-221	thymoma viral proto-oncogene 1	Mus musculus	57-60
32512269-7	2020	Here we further revealed that the inhibition of the PI3K/Akt/mTOR signaling was required for Oroxylin A to induce autophagy activation, which may be the underlying mechanism of the anti-inflammatory activity of Oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	211-221	mechanistic target of rapamycin kinase	Mus musculus	61-65
32512269-8	2020	Interestingly, mTOR overexpression completely impaired the Oroxylin A-mediated autophagy activation, and in turn, damaged the anti-inflammatory activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	59-69	mechanistic target of rapamycin kinase	Mus musculus	15-19
32512269-9	2020	Importantly, Oroxylin A inhibited PI3K/Akt/mTOR signaling by scavenging reactive oxygen species (ROS).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	thymoma viral proto-oncogene 1	Mus musculus	39-42
32512269-9	2020	Importantly, Oroxylin A inhibited PI3K/Akt/mTOR signaling by scavenging reactive oxygen species (ROS).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	mechanistic target of rapamycin kinase	Mus musculus	43-47
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	solute carrier organic anion transporter family member 1B3	Homo sapiens	125-132
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	solute carrier family 22 member 6	Homo sapiens	134-138
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	solute carrier organic anion transporter family member 1B1	Homo sapiens	116-123
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	solute carrier family 22 member 8	Homo sapiens	140-144
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	POU class 2 homeobox 2	Homo sapiens	146-150
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	solute carrier family 47 member 1	Homo sapiens	152-157
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	solute carrier family 47 member 2	Homo sapiens	163-169
32305507-3	2020	The purpose of this study is to investigate the interaction between Oroxylin A and the solute carrier transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K), and ATP-binding cassette transporters (BCRP, MDR1).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	ATP binding cassette subfamily B member 1	Homo sapiens	217-221
32305507-6	2020	Our work suggested that Oroxylin A was a substrate of OATP1B1, OATP1B3, but not a substrate of the other transporters in the concentration range of our study.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	solute carrier organic anion transporter family member 1B1	Homo sapiens	54-61
32305507-6	2020	Our work suggested that Oroxylin A was a substrate of OATP1B1, OATP1B3, but not a substrate of the other transporters in the concentration range of our study.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	solute carrier organic anion transporter family member 1B3	Homo sapiens	63-70
32305507-7	2020	Oroxylin A shows concentration-dependent inhibition of OATP1B1, OAT1, OAT3 and BCRP transportation with the half-inhibitory concentration (IC50) of 7.03, 0.961, 0.112 muM, and 0.477 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	55-62
32305507-7	2020	Oroxylin A shows concentration-dependent inhibition of OATP1B1, OAT1, OAT3 and BCRP transportation with the half-inhibitory concentration (IC50) of 7.03, 0.961, 0.112 muM, and 0.477 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	solute carrier family 22 member 6	Homo sapiens	64-68
32305507-7	2020	Oroxylin A shows concentration-dependent inhibition of OATP1B1, OAT1, OAT3 and BCRP transportation with the half-inhibitory concentration (IC50) of 7.03, 0.961, 0.112 muM, and 0.477 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	solute carrier family 22 member 8	Homo sapiens	70-74
32373542-0	2020	Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	C-X-C motif chemokine ligand 12	Homo sapiens	100-106
32289481-0	2020	Oroxylin a promotes PGC-1alpha/Mfn2 signaling to attenuate hepatocyte pyroptosis via blocking mitochondrial ROS in alcoholic liver disease.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	20-30
32289481-0	2020	Oroxylin a promotes PGC-1alpha/Mfn2 signaling to attenuate hepatocyte pyroptosis via blocking mitochondrial ROS in alcoholic liver disease.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitofusin 2	Mus musculus	31-35
32289481-6	2020	RESULT: Our study found that oroxylin A suppressed hepatocyte pyroptosis through a NLRP3 inflammasome dependent-canonical caspase-1 pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	NLR family, pyrin domain containing 3	Mus musculus	83-88
32289481-6	2020	RESULT: Our study found that oroxylin A suppressed hepatocyte pyroptosis through a NLRP3 inflammasome dependent-canonical caspase-1 pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	caspase 1	Mus musculus	122-131
32289481-7	2020	Results illuminated that oroxylin A inhibited NLRP3 inflammasome activation by reducing ROS accumulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	NLR family, pyrin domain containing 3	Mus musculus	46-51
32289481-8	2020	Furthermore, oroxylin A upregulated mitofusin 2 (Mfn2) to resist lipid deposition and mitochondria-derived ROS overproduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-21	mitofusin 2	Mus musculus	36-47
32289481-8	2020	Furthermore, oroxylin A upregulated mitofusin 2 (Mfn2) to resist lipid deposition and mitochondria-derived ROS overproduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-21	mitofusin 2	Mus musculus	49-53
32289481-9	2020	As an upstream mediator of Mfn2, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), a major regulator of mitochondria, was found to promote transcription of Mfn2 under oroxylin A treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	200-210	mitofusin 2	Mus musculus	27-31
32289481-9	2020	As an upstream mediator of Mfn2, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), a major regulator of mitochondria, was found to promote transcription of Mfn2 under oroxylin A treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	200-210	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	33-101
32289481-9	2020	As an upstream mediator of Mfn2, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), a major regulator of mitochondria, was found to promote transcription of Mfn2 under oroxylin A treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	200-210	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	103-113
32289481-9	2020	As an upstream mediator of Mfn2, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), a major regulator of mitochondria, was found to promote transcription of Mfn2 under oroxylin A treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	200-210	mitofusin 2	Mus musculus	189-193
32289481-10	2020	CONCLUSION: Our research revealed that oroxylin A could alleviate ALD via PGC-1alpha/Mfn2 signaling mediated canonical pyroptosis pathway resistance.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	74-84
32289481-10	2020	CONCLUSION: Our research revealed that oroxylin A could alleviate ALD via PGC-1alpha/Mfn2 signaling mediated canonical pyroptosis pathway resistance.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	39-49	mitofusin 2	Mus musculus	85-89
32373542-0	2020	Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	C-X-C motif chemokine receptor 4	Homo sapiens	107-112
32373542-0	2020	Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	phosphoglycolate phosphatase	Homo sapiens	113-117
32323796-0	2020	Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARgamma-dependent reversal of the progesterone receptor membrane component 1/2 expression profile.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	75-84
32323796-6	2020	Mechanistically, Oroxylin A increased peroxisome proliferator-activated receptor gamma (PPARgamma) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	peroxisome proliferator activated receptor gamma	Homo sapiens	38-86
32323796-6	2020	Mechanistically, Oroxylin A increased peroxisome proliferator-activated receptor gamma (PPARgamma) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	peroxisome proliferator activated receptor gamma	Homo sapiens	88-97
32323796-6	2020	Mechanistically, Oroxylin A increased peroxisome proliferator-activated receptor gamma (PPARgamma) expression and altered the expression profile of progesterone receptor membrane component (PGRMC)1/2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	progesterone receptor membrane component 1	Homo sapiens	148-199
32323796-7	2020	Notably, PPARgamma was revealed to play a central role in Oroxylin A-mediated anticancer activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	peroxisome proliferator activated receptor gamma	Homo sapiens	9-18
32323796-8	2020	The silencing of PPARgamma significantly abrogated Oroxylin A-induced apoptotic cell death and restored the expression profile of the PGRMC1/2 family in ovarian cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	51-61	peroxisome proliferator activated receptor gamma	Homo sapiens	17-26
31610205-0	2019	Oroxylin A regulates the turnover of lipid droplet via downregulating adipose triglyceride lipase (ATGL) in hepatic stellate cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	patatin like phospholipase domain containing 2	Homo sapiens	70-97
32999161-0	2020	Oroxylin A Exerts Its Antitumor Effects in Human Gallbladder Cancer via Inhibition of the PTEN/PI3K/AKT Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	phosphatase and tensin homolog	Homo sapiens	90-94
32999161-0	2020	Oroxylin A Exerts Its Antitumor Effects in Human Gallbladder Cancer via Inhibition of the PTEN/PI3K/AKT Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	AKT serine/threonine kinase 1	Homo sapiens	100-103
31927505-0	2020	Oroxylin A inhibits carcinogen-induced skin tumorigenesis through inhibition of inflammation by regulating SHCBP1 in mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	Shc SH2-domain binding protein 1	Mus musculus	107-113
31927505-2	2020	Oroxylin A, an active ingredient extracted from Chinese Medicine Scutellaria baicalensis, shows strong anticancer effects on multiple cancers, however, the pharmacological effect of oroxylin A on skin cancer and the regulatory effect of SHCBP1 on this process have never been evaluated.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	Shc SH2-domain binding protein 1	Mus musculus	237-243
31927505-3	2020	The present study was aimed at elucidating the effect of oroxylin A on carcinogen (DMBA/TPA)-induced skin tumorigenesis, and to further clarify the role of SHCBP1 in oroxylin A induced antitumor effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	57-67	promotion susceptibility QTL 1	Mus musculus	88-91
31927505-3	2020	The present study was aimed at elucidating the effect of oroxylin A on carcinogen (DMBA/TPA)-induced skin tumorigenesis, and to further clarify the role of SHCBP1 in oroxylin A induced antitumor effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	57-65	promotion susceptibility QTL 1	Mus musculus	88-91
31927505-4	2020	Pretreatment with oroxylin A remarkably inhibited DMBA/TPA-induced tumor formation and growth, and significantly reduced tumor incidence and the average number of tumors per mouse.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	18-28	promotion susceptibility QTL 1	Mus musculus	55-58
31927505-5	2020	Oroxylin A suppressed DMBA/TPA-induced skin hyperplasia and tumor proliferation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	promotion susceptibility QTL 1	Mus musculus	27-30
31927505-7	2020	In vitro experiments found that oroxylin A inhibited TPA-induced cell malignant transformation of skin epidermal JB6 P + cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	plasminogen activator, tissue type	Homo sapiens	53-56
31927505-8	2020	Besides, oroxylin A significantly suppressed the levels of TPA-induced inflammatory factors in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	promotion susceptibility QTL 1	Mus musculus	59-62
31927505-9	2020	Mechanistic studies showed that oroxylin A remarkably inhibited TPA-induced increased expression of SHCBP1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	promotion susceptibility QTL 1	Mus musculus	64-67
31927505-9	2020	Mechanistic studies showed that oroxylin A remarkably inhibited TPA-induced increased expression of SHCBP1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	Shc SH2-domain binding protein 1	Mus musculus	100-106
31927505-10	2020	Overexpression of SHCBP1 attenuated the oroxylin A-induced anti-inflammatory effect.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	Shc SH2-domain binding protein 1	Mus musculus	18-24
31927505-12	2020	Collectively, the anti-skin cancer effect of oroxylin A may possibly by inhibiting inflammation via suppression of SHCBP1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	Shc SH2-domain binding protein 1	Mus musculus	115-121
32082399-11	2020	Besides, oroxylin A stimulated ERalpha and ERbeta protein expression in CMECs and VSMCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	estrogen receptor 2	Rattus norvegicus	43-49
31629555-0	2020	Corrigendum to "Oroxylin A inhibits ATRA-induced IL-6 expression involved in retinoic acid syndrome by down-regulating CHOP" [Gene 551 (2014) 230-235].	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	16-26	interleukin 6	Homo sapiens	49-53
31629555-0	2020	Corrigendum to "Oroxylin A inhibits ATRA-induced IL-6 expression involved in retinoic acid syndrome by down-regulating CHOP" [Gene 551 (2014) 230-235].	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	16-26	DNA damage inducible transcript 3	Homo sapiens	119-123
31926620-0	2020	Triggering apoptosis by oroxylin A through caspase-8 activation and p62/SQSTM1 proteolysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	caspase 8	Homo sapiens	43-52
31926620-0	2020	Triggering apoptosis by oroxylin A through caspase-8 activation and p62/SQSTM1 proteolysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	sequestosome 1	Homo sapiens	68-71
31926620-0	2020	Triggering apoptosis by oroxylin A through caspase-8 activation and p62/SQSTM1 proteolysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	sequestosome 1	Homo sapiens	72-78
31926620-3	2020	Here we report that the apoptosis induced by oroxylin A was dependent on p62-mediated activation of caspase-8 in hepatocellular carcinoma cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	sequestosome 1	Homo sapiens	73-76
31926620-3	2020	Here we report that the apoptosis induced by oroxylin A was dependent on p62-mediated activation of caspase-8 in hepatocellular carcinoma cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	caspase 8	Homo sapiens	100-109
31926620-4	2020	Furthermore, oroxylin A also caused p62/SQSTM1 proteolysis at Asp329 by activating caspase-8.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	sequestosome 1	Homo sapiens	36-39
31926620-4	2020	Furthermore, oroxylin A also caused p62/SQSTM1 proteolysis at Asp329 by activating caspase-8.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	sequestosome 1	Homo sapiens	40-46
31926620-4	2020	Furthermore, oroxylin A also caused p62/SQSTM1 proteolysis at Asp329 by activating caspase-8.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	caspase 8	Homo sapiens	83-92
31926620-5	2020	Further studies confirm that mutation in p62 (D329H and D329G) was resistant to oroxylin A-mediated p62 cleavage and apoptosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	sequestosome 1	Homo sapiens	41-44
31926620-5	2020	Further studies confirm that mutation in p62 (D329H and D329G) was resistant to oroxylin A-mediated p62 cleavage and apoptosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	sequestosome 1	Homo sapiens	100-103
31926620-7	2020	In vivo, p62 similarly contributed to oroxylin A-exerted antitumor effect in xenograft model inoculated SMMC-7721 tumor.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	sequestosome 1	Homo sapiens	9-12
31926620-8	2020	In conclusion, our findings indicated that oroxylin A triggered apoptosis through caspase-8 activation and p62/SQSTM1 proteolysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	caspase 8	Homo sapiens	82-91
31926620-8	2020	In conclusion, our findings indicated that oroxylin A triggered apoptosis through caspase-8 activation and p62/SQSTM1 proteolysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	sequestosome 1	Homo sapiens	107-110
31926620-8	2020	In conclusion, our findings indicated that oroxylin A triggered apoptosis through caspase-8 activation and p62/SQSTM1 proteolysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	sequestosome 1	Homo sapiens	111-117
31884961-0	2019	Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	phosphatase and tensin homolog	Homo sapiens	35-39
31884961-0	2019	Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	MDM2 proto-oncogene	Homo sapiens	72-76
31884961-0	2019	Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	sirtuin 3	Homo sapiens	95-100
31884961-0	2019	Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	tumor protein p53	Homo sapiens	137-140
31884961-0	2019	Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	tumor protein p53	Homo sapiens	170-173
31610205-0	2019	Oroxylin A regulates the turnover of lipid droplet via downregulating adipose triglyceride lipase (ATGL) in hepatic stellate cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	patatin like phospholipase domain containing 2	Homo sapiens	99-103
31610205-5	2019	Interestingly, oroxylin A treatment observably decreased the expression of adipose triglyceride lipase (ATGL) without large differences in classical LD synthesis pathway, LD-related transcription factors, and autophagy pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	patatin like phospholipase domain containing 2	Homo sapiens	75-102
31610205-5	2019	Interestingly, oroxylin A treatment observably decreased the expression of adipose triglyceride lipase (ATGL) without large differences in classical LD synthesis pathway, LD-related transcription factors, and autophagy pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	patatin like phospholipase domain containing 2	Homo sapiens	104-108
31610205-6	2019	ATGL overexpression could completely impair the effect of oroxylin A on reversing LD content.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	patatin like phospholipase domain containing 2	Homo sapiens	0-4
31610205-7	2019	Importantly, reactive oxygen species (ROS) signaling pathway mediated oroxylin A-induced ATGL downregulation and LD revision in activated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	70-80	patatin like phospholipase domain containing 2	Homo sapiens	89-93
31610205-10	2019	Taken together, our study reveals the important molecular mechanism of anti-fibrosis effect of oroxylin A, and also suggests that ROS-ATGL pathway is a potential target for reversing LDs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	95-105	patatin like phospholipase domain containing 2	Homo sapiens	134-138
31608242-0	2019	Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-21	C-X-C motif chemokine ligand 12	Homo sapiens	101-107
31608242-0	2019	Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-21	C-X-C motif chemokine receptor 4	Homo sapiens	108-113
31024831-0	2019	Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	C-X-C motif chemokine ligand 12	Homo sapiens	88-94
31341911-0	2019	Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-kappaB Signaling Pathway in Human Breast Cancer Cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	nuclear factor kappa B subunit 1	Homo sapiens	69-78
31341911-12	2019	Besides, Oroxylin A suppressed the expression of inflammatory factors and NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	nuclear factor kappa B subunit 1	Homo sapiens	74-83
31341911-13	2019	Furthermore, we also found that supplement of TNF-alpha reversed the effects of Oroxylin A on the cell proliferation, invasion, migration, and EMT in breast cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	80-90	tumor necrosis factor	Homo sapiens	46-55
31341911-14	2019	Taken together, our results suggested that Oroxylin A inhibited the cell proliferation, invasion, migration, and EMT through inactivating NF-kappaB signaling pathway in human breast cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	nuclear factor kappa B subunit 1	Homo sapiens	138-147
30790579-4	2019	Five flavonoids, including tangeretin, sinensetin, isosinensetin, sciadopitysin and oroxylin A exhibited significant inhibition on P-gp in MDR1-MDCKIIcells, which reduced the P-gp-mediated efflux of paraquat and taxol and consequently increased their cell toxicity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
30790579-4	2019	Five flavonoids, including tangeretin, sinensetin, isosinensetin, sciadopitysin and oroxylin A exhibited significant inhibition on P-gp in MDR1-MDCKIIcells, which reduced the P-gp-mediated efflux of paraquat and taxol and consequently increased their cell toxicity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	175-179
30790292-0	2019	Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1alpha/hedgehog pathway under hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-103
30790292-4	2019	Oroxylin A (C16H12O5), a bioactive flavonoid, could induce HIF-1alpha degradation via prolyl-hydroxylases-VHL signaling pathway, resulting in the inactivation of the hedgehog.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
30790292-5	2019	Besides, oroxylin A increased the expression of Sufu, which is a negative regulator of Gli1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	SUFU negative regulator of hedgehog signaling	Homo sapiens	48-52
30790292-5	2019	Besides, oroxylin A increased the expression of Sufu, which is a negative regulator of Gli1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	GLI family zinc finger 1	Homo sapiens	87-91
30790292-8	2019	In conclusion, our results demonstrated that HIF-1alpha/hedgehog pathway conferred TMZ resistance under hypoxia, and oroxylin A was capable of increasing the sensitivity of TMZ on glioma cells in vitro and in vivo by inhibiting HIF-1alpha/hedgehog pathway and depressing the activation of Gli1 directly.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	117-127	hypoxia inducible factor 1 subunit alpha	Homo sapiens	228-238
30790292-8	2019	In conclusion, our results demonstrated that HIF-1alpha/hedgehog pathway conferred TMZ resistance under hypoxia, and oroxylin A was capable of increasing the sensitivity of TMZ on glioma cells in vitro and in vivo by inhibiting HIF-1alpha/hedgehog pathway and depressing the activation of Gli1 directly.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	117-127	GLI family zinc finger 1	Homo sapiens	289-293
31024831-6	2019	Moreover, the reverse effect of IM resistance by Oroxylin A was demonstrated by the inhibition of beta-catenin/P-gp pathway via the decrease of CXCR4 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	49-59	catenin beta 1	Homo sapiens	98-110
31024831-6	2019	Moreover, the reverse effect of IM resistance by Oroxylin A was demonstrated by the inhibition of beta-catenin/P-gp pathway via the decrease of CXCR4 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	49-59	phosphoglycolate phosphatase	Homo sapiens	111-115
31024831-6	2019	Moreover, the reverse effect of IM resistance by Oroxylin A was demonstrated by the inhibition of beta-catenin/P-gp pathway via the decrease of CXCR4 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	49-59	C-X-C motif chemokine receptor 4	Homo sapiens	144-149
31024831-7	2019	The in vivo study also showed that Oroxylin A could decrease the expression of P-gp and beta-catenin in mice bone marrow with low toxicity, which could be consistent with the mechanisms verified in vitro studies.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	phosphoglycolate phosphatase	Mus musculus	79-83
31024831-7	2019	The in vivo study also showed that Oroxylin A could decrease the expression of P-gp and beta-catenin in mice bone marrow with low toxicity, which could be consistent with the mechanisms verified in vitro studies.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	catenin (cadherin associated protein), beta 1	Mus musculus	88-100
31024831-8	2019	In conclusion, all these results showed that Oroxylin A improved the sensitivity of K562 and KU812 cells to IM in BM microenvironment by decreasing the expression of CXCR4 and then inhibiting beta-catenin/P-gp pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	C-X-C motif chemokine receptor 4	Homo sapiens	166-171
31024831-8	2019	In conclusion, all these results showed that Oroxylin A improved the sensitivity of K562 and KU812 cells to IM in BM microenvironment by decreasing the expression of CXCR4 and then inhibiting beta-catenin/P-gp pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	catenin beta 1	Homo sapiens	192-204
31024831-8	2019	In conclusion, all these results showed that Oroxylin A improved the sensitivity of K562 and KU812 cells to IM in BM microenvironment by decreasing the expression of CXCR4 and then inhibiting beta-catenin/P-gp pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	phosphoglycolate phosphatase	Homo sapiens	205-209
31024831-0	2019	Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	C-X-C motif chemokine receptor 4	Homo sapiens	95-100
31024831-0	2019	Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	phosphoglycolate phosphatase	Homo sapiens	101-105
30680817-6	2019	In MCF-7 cells, compared with baicalein-treated groups, oroxylin A with lower doses decreased and increased the formation of 4-OHE2 and 2-hydroxyestradiol, respectively, with a preferential induction of mRNA of CYP1A1 over CYP1B1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	56-66	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	211-217
30680817-0	2019	Oroxylin A, a methylated metabolite of baicalein, exhibits a stronger inhibitory effect than baicalein on the CYP1B1-mediated carcinogenic estradiol metabolite formation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	110-116
30680817-2	2019	In this study, inhibitory effects of flavonoids baicalein and oroxylin A, a metabolite of baicalein in human body, on CYP1A1 and 1B1 activities were investigated in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	62-72	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	118-132
30680817-6	2019	In MCF-7 cells, compared with baicalein-treated groups, oroxylin A with lower doses decreased and increased the formation of 4-OHE2 and 2-hydroxyestradiol, respectively, with a preferential induction of mRNA of CYP1A1 over CYP1B1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	56-66	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	223-229
30680817-3	2019	The inhibition intensities of baicalein and oroxylin A towards CYP1B1 were greater than towards CYP1A1 with a mixed mechanism.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	63-69
30680817-7	2019	In conclusion, this study demonstrated that oroxylin A showed a stronger inhibitory effect than baicalein on CYP1B1-mediated 4-OHE2 formation in MCF-7 cells, providing crucial implications for their possibly preventive/therapeutic potential against breast cancer via inhibition of CYP1B1, particularly of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	109-115
30680817-3	2019	The inhibition intensities of baicalein and oroxylin A towards CYP1B1 were greater than towards CYP1A1 with a mixed mechanism.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	96-102
30680817-4	2019	In addition, oroxylin A showed a stronger inhibitory effect than baicalein towards the CYP1B1-mediated 17beta-estradiol 4-hydroxylation, with the IC50 values of 0.0146 and 2.27 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	87-93
30680817-7	2019	In conclusion, this study demonstrated that oroxylin A showed a stronger inhibitory effect than baicalein on CYP1B1-mediated 4-OHE2 formation in MCF-7 cells, providing crucial implications for their possibly preventive/therapeutic potential against breast cancer via inhibition of CYP1B1, particularly of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	281-287
30680817-4	2019	In addition, oroxylin A showed a stronger inhibitory effect than baicalein towards the CYP1B1-mediated 17beta-estradiol 4-hydroxylation, with the IC50 values of 0.0146 and 2.27 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	latexin	Homo sapiens	177-180
30680817-7	2019	In conclusion, this study demonstrated that oroxylin A showed a stronger inhibitory effect than baicalein on CYP1B1-mediated 4-OHE2 formation in MCF-7 cells, providing crucial implications for their possibly preventive/therapeutic potential against breast cancer via inhibition of CYP1B1, particularly of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	305-315	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	109-115
30680817-5	2019	Docking studies elucidated that oroxylin A had a stronger binding affinity than baicalein for CYP1B1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	94-100
30744642-0	2019	Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	48-58	lactate dehydrogenase A	Mus musculus	77-100
30871117-0	2019	Long-Term Exposure to Oroxylin A Inhibits Metastasis by Suppressing CCL2 in Oral Squamous Cell Carcinoma Cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	C-C motif chemokine ligand 2	Homo sapiens	68-72
30318784-0	2019	Oroxylin A inhibits Kaposi"s sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARgamma/Prox1 axis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	K2	Human gammaherpesvirus 8	68-73
30318784-0	2019	Oroxylin A inhibits Kaposi"s sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARgamma/Prox1 axis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	156-165
30318784-0	2019	Oroxylin A inhibits Kaposi"s sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARgamma/Prox1 axis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	prospero homeobox 1	Homo sapiens	166-171
30318784-2	2019	This study was aimed to investigate the effect of Chinese herb oroxylin A on lymphatic reprogramming and neovascularization by KSHV vIL-6 in vitro and in vivo.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	63-73	K2	Human gammaherpesvirus 8	132-137
30318784-10	2019	Oroxylin A induced cellular invasion abrogation, apoptosis induction, and neovascularization inhibition of the vIL-6-expressing endothelial cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	K2	Human gammaherpesvirus 8	111-116
30318784-11	2019	Mechanically, oroxylin A elevated PPARgamma expression, which in turn interacted with and facilitated Prox1 to undergo ubiquitinational degradation, and subsequently leads to VEGFR3, LYVE-1, and podoplanin reduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	peroxisome proliferator activated receptor gamma	Homo sapiens	34-43
30318784-11	2019	Mechanically, oroxylin A elevated PPARgamma expression, which in turn interacted with and facilitated Prox1 to undergo ubiquitinational degradation, and subsequently leads to VEGFR3, LYVE-1, and podoplanin reduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	prospero homeobox 1	Homo sapiens	102-107
30318784-11	2019	Mechanically, oroxylin A elevated PPARgamma expression, which in turn interacted with and facilitated Prox1 to undergo ubiquitinational degradation, and subsequently leads to VEGFR3, LYVE-1, and podoplanin reduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	fms related receptor tyrosine kinase 4	Homo sapiens	175-181
30318784-11	2019	Mechanically, oroxylin A elevated PPARgamma expression, which in turn interacted with and facilitated Prox1 to undergo ubiquitinational degradation, and subsequently leads to VEGFR3, LYVE-1, and podoplanin reduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	lymphatic vessel endothelial hyaluronan receptor 1	Homo sapiens	183-189
30318784-11	2019	Mechanically, oroxylin A elevated PPARgamma expression, which in turn interacted with and facilitated Prox1 to undergo ubiquitinational degradation, and subsequently leads to VEGFR3, LYVE-1, and podoplanin reduction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	podoplanin	Homo sapiens	195-205
30318784-12	2019	CONCLUSION: Through modulating PPARgamma/Prox1 axis, oroxylin A inhibits lymphatic reprogramming and neovascularization of KSHV vIL-6.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	53-63	peroxisome proliferator activated receptor gamma	Homo sapiens	31-40
30318784-12	2019	CONCLUSION: Through modulating PPARgamma/Prox1 axis, oroxylin A inhibits lymphatic reprogramming and neovascularization of KSHV vIL-6.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	53-63	prospero homeobox 1	Homo sapiens	41-46
30318784-12	2019	CONCLUSION: Through modulating PPARgamma/Prox1 axis, oroxylin A inhibits lymphatic reprogramming and neovascularization of KSHV vIL-6.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	53-63	K2	Human gammaherpesvirus 8	128-133
30744642-10	2019	However, adenovirus-mediated overexpression of LDH-A significantly counteracted the oroxylin A"s effects in fibrotic mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	84-94	lactate dehydrogenase A	Mus musculus	47-52
30744642-11	2019	CONCLUSIONS: Blockade of aerobic glycolysis by oroxylin A via inhibition of LDH-A reduced HSC contraction and attenuated liver fibrosis, suggesting LDH-A as a promising target for intervention of hepatic fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	47-57	lactate dehydrogenase A	Mus musculus	76-81
30744642-11	2019	CONCLUSIONS: Blockade of aerobic glycolysis by oroxylin A via inhibition of LDH-A reduced HSC contraction and attenuated liver fibrosis, suggesting LDH-A as a promising target for intervention of hepatic fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	47-57	lactate dehydrogenase A	Mus musculus	148-153
30744642-6	2019	Oroxylin A also decreased extracellular acidification rate and inhibited the expression and activity of glycolysis rate-limiting enzymes (hexose kinase 2, phosphofructokinase 1 and pyruvate kinas type M2) in HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	phosphofructokinase, liver, B-type	Mus musculus	138-176
30744642-8	2019	Furthermore, oroxylin A inhibited the expression and activity of lactate dehydrogenase-A (LDH-A) in HSCs, which was required for oroxylin A blockade of glycolysis and suppression of contraction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	lactate dehydrogenase A	Mus musculus	65-88
30744642-8	2019	Furthermore, oroxylin A inhibited the expression and activity of lactate dehydrogenase-A (LDH-A) in HSCs, which was required for oroxylin A blockade of glycolysis and suppression of contraction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	lactate dehydrogenase A	Mus musculus	90-95
30744642-8	2019	Furthermore, oroxylin A inhibited the expression and activity of lactate dehydrogenase-A (LDH-A) in HSCs, which was required for oroxylin A blockade of glycolysis and suppression of contraction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	129-139	lactate dehydrogenase A	Mus musculus	65-88
30744642-8	2019	Furthermore, oroxylin A inhibited the expression and activity of lactate dehydrogenase-A (LDH-A) in HSCs, which was required for oroxylin A blockade of glycolysis and suppression of contraction.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	129-139	lactate dehydrogenase A	Mus musculus	90-95
30195877-11	2018	The transcription levels of Salmonella pathogenicity island 1 virulence associated genes (sopB, sopE, sopE2) of S. typhimurium in the presence of baicalin, baicalein, and oroxylin A were detected by qRT-PCR.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	171-181	plasmid-partitioning protein	Salmonella enterica subsp. enterica serovar Typhimurium	90-94
29346508-0	2018	Oroxylin A, a natural compound, mitigates the negative effects of TNFalpha-treated acute myelogenous leukemia cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor necrosis factor	Homo sapiens	66-74
29346508-5	2018	The present study demonstrates that oroxylin A, a natural compound isolated from Scutellariae radix, sensitizes leukemia cells to TNFalpha and markedly enhances TNFalpha-induced growth inhibition and differentiation of AML cell including human leukemia cell lines and primary AML cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	tumor necrosis factor	Homo sapiens	130-138
29346508-5	2018	The present study demonstrates that oroxylin A, a natural compound isolated from Scutellariae radix, sensitizes leukemia cells to TNFalpha and markedly enhances TNFalpha-induced growth inhibition and differentiation of AML cell including human leukemia cell lines and primary AML cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	tumor necrosis factor	Homo sapiens	161-169
29346508-6	2018	Activation of PI3K/AKT pathway could be inhibited by oroxylin A through inhibiting expression of tRXRalpha in NB4 and HL-60-resistant cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	53-63	AKT serine/threonine kinase 1	Homo sapiens	19-22
29346508-7	2018	Furthermore, we found that oroxylin A inhibited the activation of NF-kappaB and the DNA binding activity by TNFalpha proved by EMSA in these two AML cell lines.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	tumor necrosis factor	Homo sapiens	108-116
29346508-9	2018	Overall, our results indicate that oroxylin A is able to inhibit the negative effects of TNFalpha for AML therapy, suggesting that combination of oroxylin A and TNFalpha have the potential to delay growth or eliminate the abnormal leukemic cells, thus representing a promising strategy for AML treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	tumor necrosis factor	Homo sapiens	89-97
29346508-9	2018	Overall, our results indicate that oroxylin A is able to inhibit the negative effects of TNFalpha for AML therapy, suggesting that combination of oroxylin A and TNFalpha have the potential to delay growth or eliminate the abnormal leukemic cells, thus representing a promising strategy for AML treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	tumor necrosis factor	Homo sapiens	146-169
30195877-18	2018	Sub-MICs of baicalin, baicalein, and oroxylin A also significantly decreased the levels of TNFalpha, nitrate, and LDH from S. typhimurium-infected Caco-2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	37-47	tumor necrosis factor	Mus musculus	91-99
30195877-19	2018	Moreover, the transcription levels of sopB, sopE, and sopE2 were significantly suppressed by baicalin, baicalein, and oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	118-128	plasmid-partitioning protein	Salmonella enterica subsp. enterica serovar Typhimurium	38-42
28857294-0	2018	Oroxylin A prevents angiogenesis of LSECs in liver fibrosis via inhibition of YAP/HIF-1alpha signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	yes-associated protein 1	Mus musculus	78-81
29318697-0	2018	Oroxylin A inhibits ethanol-induced hepatocyte senescence via YAP pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	Yes1 associated transcriptional regulator	Homo sapiens	62-65
29318697-8	2018	We found that oroxylin A inhibited ethanol-induced hepatocyte senescence by decreasing the number of SA-beta-gal-positive LO2 cells and reducing the expression of senescence markers p16, p21 and Hmga1 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	SH3 domain binding protein 5	Homo sapiens	101-108
29318697-8	2018	We found that oroxylin A inhibited ethanol-induced hepatocyte senescence by decreasing the number of SA-beta-gal-positive LO2 cells and reducing the expression of senescence markers p16, p21 and Hmga1 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	cyclin dependent kinase inhibitor 2A	Homo sapiens	182-185
29318697-8	2018	We found that oroxylin A inhibited ethanol-induced hepatocyte senescence by decreasing the number of SA-beta-gal-positive LO2 cells and reducing the expression of senescence markers p16, p21 and Hmga1 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	H3 histone pseudogene 16	Homo sapiens	187-190
29318697-8	2018	We found that oroxylin A inhibited ethanol-induced hepatocyte senescence by decreasing the number of SA-beta-gal-positive LO2 cells and reducing the expression of senescence markers p16, p21 and Hmga1 in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	high mobility group AT-hook 1	Homo sapiens	195-200
29318697-10	2018	Of importance, we revealed that YAP pharmacological inhibitor verteporfin or YAP siRNA eliminated the effect of oroxylin A on ethanol-induced hepatocyte senescence in vitro, and this was further supported by the evidence in vivo experiments.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	112-122	Yes1 associated transcriptional regulator	Homo sapiens	32-35
29318697-10	2018	Of importance, we revealed that YAP pharmacological inhibitor verteporfin or YAP siRNA eliminated the effect of oroxylin A on ethanol-induced hepatocyte senescence in vitro, and this was further supported by the evidence in vivo experiments.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	112-122	Yes1 associated transcriptional regulator	Homo sapiens	77-80
29318697-11	2018	CONCLUSION: Therefore, these aggregated data suggested that oroxylin A relieved alcoholic liver injury possibly by inhibiting the senescence of hepatocyte, which was dependent on its activation of YAP in hepatocytes.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	60-68	Yes1 associated transcriptional regulator	Homo sapiens	197-200
29476730-0	2018	Oroxylin A prevents alcohol-induced hepatic steatosis through inhibition of hypoxia inducible factor 1alpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	76-107
29476730-8	2018	Moreover, oroxylin A significantly suppressed the nuclear translocation of HIF-1alpha in ethanol-treated LO2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	hypoxia inducible factor 1 subunit alpha	Homo sapiens	75-85
29476730-9	2018	Furthermore, activation of HIF-1alpha significantly attenuated the effect of oroxylin A on lipid droplets accumulation and genes related to lipid metabolism in vitro and in vivo.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	77-87	hypoxia inducible factor 1 subunit alpha	Homo sapiens	27-37
29476730-10	2018	Altogether, we demonstrated a HIF-1alpha-associated mechanism underlying oroxylin A inhibition of lipid deposition in ethanol-stimulated LO2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	73-83	hypoxia inducible factor 1 subunit alpha	Homo sapiens	30-40
29476730-11	2018	Oroxylin A modulation of HIF-1alpha level may represent a therapeutic remedy for ALD.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-35
29414645-6	2018	We found that treatment with Oroxylin A markedly decreased the level of liver injury markers, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	122-148
29414645-6	2018	We found that treatment with Oroxylin A markedly decreased the level of liver injury markers, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	150-153
29414645-6	2018	We found that treatment with Oroxylin A markedly decreased the level of liver injury markers, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	glutamic pyruvic transaminase, soluble	Mus musculus	160-184
29414645-6	2018	We found that treatment with Oroxylin A markedly decreased the level of liver injury markers, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	glutamic pyruvic transaminase, soluble	Mus musculus	186-189
29414645-7	2018	Moreover, Oroxylin A treatment remarkably inhibited extracellular matrix (ECM) deposition, and significantly down-regulated the mRNA and protein expression of liver fibrosis markers including alpha1(I)collagen, fibronectin, alpha-smooth muscle actin (alpha-SMA), PDGF-betaR, and TGF-betaR1 in CCl4-induced murine model of liver fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	fibronectin 1	Mus musculus	211-222
29414645-7	2018	Moreover, Oroxylin A treatment remarkably inhibited extracellular matrix (ECM) deposition, and significantly down-regulated the mRNA and protein expression of liver fibrosis markers including alpha1(I)collagen, fibronectin, alpha-smooth muscle actin (alpha-SMA), PDGF-betaR, and TGF-betaR1 in CCl4-induced murine model of liver fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	actin alpha 2, smooth muscle, aorta	Mus musculus	224-249
29414645-7	2018	Moreover, Oroxylin A treatment remarkably inhibited extracellular matrix (ECM) deposition, and significantly down-regulated the mRNA and protein expression of liver fibrosis markers including alpha1(I)collagen, fibronectin, alpha-smooth muscle actin (alpha-SMA), PDGF-betaR, and TGF-betaR1 in CCl4-induced murine model of liver fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	actin alpha 2, smooth muscle, aorta	Mus musculus	251-260
29414645-7	2018	Moreover, Oroxylin A treatment remarkably inhibited extracellular matrix (ECM) deposition, and significantly down-regulated the mRNA and protein expression of liver fibrosis markers including alpha1(I)collagen, fibronectin, alpha-smooth muscle actin (alpha-SMA), PDGF-betaR, and TGF-betaR1 in CCl4-induced murine model of liver fibrosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	chemokine (C-X-C motif) ligand 11	Mus musculus	283-289
29414645-8	2018	Furthermore, experimental results in vitro showed that Oroxylin A treatment reduced the mRNA and protein expression of HSC activation markers, alpha-SMA, desmin, alpha1 (I) collagen, fibronectin, TGF-beta, and TNF-alpha, in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	actin alpha 2, smooth muscle, aorta	Mus musculus	143-152
29414645-8	2018	Furthermore, experimental results in vitro showed that Oroxylin A treatment reduced the mRNA and protein expression of HSC activation markers, alpha-SMA, desmin, alpha1 (I) collagen, fibronectin, TGF-beta, and TNF-alpha, in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	desmin	Mus musculus	154-160
29414645-8	2018	Furthermore, experimental results in vitro showed that Oroxylin A treatment reduced the mRNA and protein expression of HSC activation markers, alpha-SMA, desmin, alpha1 (I) collagen, fibronectin, TGF-beta, and TNF-alpha, in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	fibronectin 1	Mus musculus	183-194
29414645-8	2018	Furthermore, experimental results in vitro showed that Oroxylin A treatment reduced the mRNA and protein expression of HSC activation markers, alpha-SMA, desmin, alpha1 (I) collagen, fibronectin, TGF-beta, and TNF-alpha, in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	transforming growth factor, beta 1	Mus musculus	196-204
29414645-8	2018	Furthermore, experimental results in vitro showed that Oroxylin A treatment reduced the mRNA and protein expression of HSC activation markers, alpha-SMA, desmin, alpha1 (I) collagen, fibronectin, TGF-beta, and TNF-alpha, in a dose dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	tumor necrosis factor	Mus musculus	210-219
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	microtubule-associated protein 1 light chain 3 beta	Mus musculus	98-103
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	autophagy related 3	Mus musculus	105-109
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	autophagy related 5	Mus musculus	117-121
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	beclin 1, autophagy related	Mus musculus	123-130
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	beclin 1, autophagy related	Mus musculus	131-135
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	autophagy related 7	Mus musculus	137-141
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	autophagy related 9A	Mus musculus	143-147
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	autophagy related 12	Mus musculus	149-154
29414645-9	2018	Attractively, Oroxylin A treatment also markedly up-regulated the expression of autophagy makers, LC3-B, Atg3, Atg4, Atg5, Beclin1/Atg6, Atg7, Atg9, ATG12, and Atg14, and apparently reduced the expression of autophagy substrate p62 in both CCl4-induced murine model of liver fibrosis and PDGF-BB-treated HSCs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	autophagy related 14	Mus musculus	160-165
28857294-6	2018	We next found that oroxylin A inhibited hypoxia-induced nuclear translocation of YAP, which may influence the accumulation of HIF-1alpha and subsequently decrease transcription of downstream target gene including VEGF-A and Ang-2, thereby exerting an anti-angiogenic activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	yes-associated protein 1	Mus musculus	81-84
28857294-6	2018	We next found that oroxylin A inhibited hypoxia-induced nuclear translocation of YAP, which may influence the accumulation of HIF-1alpha and subsequently decrease transcription of downstream target gene including VEGF-A and Ang-2, thereby exerting an anti-angiogenic activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	hypoxia inducible factor 1, alpha subunit	Mus musculus	126-136
28857294-6	2018	We next found that oroxylin A inhibited hypoxia-induced nuclear translocation of YAP, which may influence the accumulation of HIF-1alpha and subsequently decrease transcription of downstream target gene including VEGF-A and Ang-2, thereby exerting an anti-angiogenic activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	vascular endothelial growth factor A	Mus musculus	213-219
28857294-6	2018	We next found that oroxylin A inhibited hypoxia-induced nuclear translocation of YAP, which may influence the accumulation of HIF-1alpha and subsequently decrease transcription of downstream target gene including VEGF-A and Ang-2, thereby exerting an anti-angiogenic activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	angiopoietin 2	Mus musculus	224-229
28857294-0	2018	Oroxylin A prevents angiogenesis of LSECs in liver fibrosis via inhibition of YAP/HIF-1alpha signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1, alpha subunit	Mus musculus	82-92
28857294-2	2018	Here we established murine model of liver fibrosis and found that oroxylin A (40 mg/kg) could ameliorate angiogenesis in liver fibrosis may related to hypoxia inducible factor 1alpha (HIF-1alpha).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	66-76	hypoxia inducible factor 1, alpha subunit	Mus musculus	151-182
28857294-2	2018	Here we established murine model of liver fibrosis and found that oroxylin A (40 mg/kg) could ameliorate angiogenesis in liver fibrosis may related to hypoxia inducible factor 1alpha (HIF-1alpha).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	66-76	hypoxia inducible factor 1, alpha subunit	Mus musculus	184-194
28857294-4	2018	Hypoxia induced vascular endothelial growth factor A (VEGF-A), angiopoietin 2 (Ang-2), and platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) elevated in LSECs were reduced by oroxylin A or acriflavine (ACF, an HIF-1alpha inhibitor), indicating HIF-1alpha involved the angiogenesis of LSECs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	186-196	platelet/endothelial cell adhesion molecule 1	Mus musculus	138-145
28938606-4	2017	The production of IL-1beta, IL-6 and TNF-alpha in colon was also markedly reduced by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	85-95	interleukin 1 beta	Mus musculus	18-26
28536775-5	2017	RESULTS: The first-step metabolite of baicalein was isolated and identified as oroxylin A; soluble-bound COMT (S-COMT) was the major enzyme responsible for its biotransformation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	79-89	catechol-O-methyltransferase	Homo sapiens	105-109
28536775-5	2017	RESULTS: The first-step metabolite of baicalein was isolated and identified as oroxylin A; soluble-bound COMT (S-COMT) was the major enzyme responsible for its biotransformation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	79-89	catechol-O-methyltransferase	Homo sapiens	113-117
28536775-7	2017	Meantime, oroxylin A was rapidly metabolized by UGTs, UGT1A1, -1A3, -1A6, -1A7, -1A8, -1A9, and -1A10 which were involved in the glucuronidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	54-60
28426226-12	2017	The high brain uptake of oroxylin A, a GABAA antagonist which had been reported to antagonize diazepam-induced anxiolytic effect, might have suppressed the anxiolytic effects of the other flavones and account for the lack of overall anxiolytic effect of SR extract.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	39-44
28938606-0	2017	Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	NLR family, pyrin domain containing 3	Mus musculus	44-49
28938606-4	2017	The production of IL-1beta, IL-6 and TNF-alpha in colon was also markedly reduced by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	85-95	interleukin 6	Mus musculus	28-32
28938606-4	2017	The production of IL-1beta, IL-6 and TNF-alpha in colon was also markedly reduced by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	85-95	tumor necrosis factor	Mus musculus	37-46
28726775-0	2017	Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hepatocyte nuclear factor 4 alpha	Homo sapiens	26-36
28938606-5	2017	Moreover, oroxylin A significantly decreased the expression of NLRP3 in intestinal mucosal tissue.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	NLR family, pyrin domain containing 3	Mus musculus	63-68
28938606-7	2017	Further study found that the activation of NLRP3 inflammasome was dose-dependently inhibited by oroxylin A in both THP-Ms and BMDMs, followed by decrease in the cleavage of caspase-1 and secretion of IL-1beta.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	96-106	NLR family, pyrin domain containing 3	Mus musculus	43-48
28938606-7	2017	Further study found that the activation of NLRP3 inflammasome was dose-dependently inhibited by oroxylin A in both THP-Ms and BMDMs, followed by decrease in the cleavage of caspase-1 and secretion of IL-1beta.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	96-106	interleukin 1 beta	Mus musculus	200-208
28938606-8	2017	This inhibitory effect of oroxylin A was due to restraint of the NLRP3 protein expression and the inflammasome formation in macrophages.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	NLR family, pyrin domain containing 3	Mus musculus	65-70
28938606-9	2017	Furthermore, the reduction of NLRP3 protein expression by oroxylin A was dependent on the inhibition of NF-kappaB p65 expression and nuclear translocation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	NLR family, pyrin domain containing 3	Mus musculus	30-35
28938606-9	2017	Furthermore, the reduction of NLRP3 protein expression by oroxylin A was dependent on the inhibition of NF-kappaB p65 expression and nuclear translocation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	104-113
28938606-9	2017	Furthermore, the reduction of NLRP3 protein expression by oroxylin A was dependent on the inhibition of NF-kappaB p65 expression and nuclear translocation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	114-117
28938606-10	2017	Besides, oroxylin A directly suppressed the ASC speck formation and the inflammasome assembly which in turn restrained the activation of NLRP3 inflammasome.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	steroid sulfatase	Mus musculus	44-47
28938606-10	2017	Besides, oroxylin A directly suppressed the ASC speck formation and the inflammasome assembly which in turn restrained the activation of NLRP3 inflammasome.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	NLR family, pyrin domain containing 3	Mus musculus	137-142
28938606-11	2017	Our findings demonstrated that oroxylin A inhibited NLRP3 inflammasome activation and could potentially be used for the treatment of IBD.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	31-41	NLR family, pyrin domain containing 3	Mus musculus	52-57
28594405-0	2017	Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1alpha-modulated fatty acid metabolism.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	91-100
28640893-7	2017	RESULTS: Two weeks after the insult, the oroxylin A-treated group had significantly higher FG labeled cells and Brn3a+ cells suggesting preserved RGC density in the central and mid-peripheral retinas compared with those of the PBS-treated group.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	41-51	POU class 4 homeobox 1	Rattus norvegicus	112-117
28640893-11	2017	Increased GFAP expression in the retina was reduced greatly in ON-crushed, oroxylin A-treated group.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	75-85	glial fibrillary acidic protein	Rattus norvegicus	10-14
28640893-12	2017	Furthermore, administration of oroxylin A significantly attenuated ON crush insult-induced iNOS and COX-2 expression in the retinas.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	31-41	nitric oxide synthase 2	Rattus norvegicus	91-95
28640893-12	2017	Furthermore, administration of oroxylin A significantly attenuated ON crush insult-induced iNOS and COX-2 expression in the retinas.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	31-41	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	100-105
28594405-7	2017	Oroxylin A inactivated HIF1alpha and reprogrammed fatty acid metabolism of HCT116 cells, decreasing intracellular fatty acid level and enhancing fatty acid oxidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-32
27764743-0	2016	Oroxylin A attenuates cigarette smoke-induced lung inflammation by activating Nrf2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	78-82
27820974-4	2017	Oroxylin A significantly reduced the levels of intracellular calcium and reactive oxygen species and increased the levels of CAT and Mn/SOD.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	catalase	Rattus norvegicus	125-128
27820974-4	2017	Oroxylin A significantly reduced the levels of intracellular calcium and reactive oxygen species and increased the levels of CAT and Mn/SOD.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	superoxide dismutase 2	Rattus norvegicus	133-139
27820974-5	2017	Oroxylin A also inhibited the activation of caspase-3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	caspase 3	Rattus norvegicus	44-53
27585443-8	2017	Besides, Oroxylin A could obviously radiosensitize ESCC cells by arresting tumor cells in G2/M phase and regulating cyclin B1 and Cdc 2 protein expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	cyclin B1	Homo sapiens	116-125
27585443-8	2017	Besides, Oroxylin A could obviously radiosensitize ESCC cells by arresting tumor cells in G2/M phase and regulating cyclin B1 and Cdc 2 protein expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	cyclin dependent kinase 1	Homo sapiens	130-135
27533597-0	2017	Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	C-X-C motif chemokine ligand 12	Homo sapiens	98-104
27533597-0	2017	Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	atypical chemokine receptor 3	Homo sapiens	105-110
27533597-11	2017	In conclusion, oroxylin A improved sensitivity of CML cells to IM treatment in BM microenvironment through regulating CXCL12/CXCR7 pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	C-X-C motif chemokine ligand 12	Homo sapiens	118-124
27533597-11	2017	In conclusion, oroxylin A improved sensitivity of CML cells to IM treatment in BM microenvironment through regulating CXCL12/CXCR7 pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	atypical chemokine receptor 3	Homo sapiens	125-130
26741501-8	2016	We found oroxylin A could reverse TGFbeta1-induced epithelial-mesenchymal transition by inhibiting Snail expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	snail family transcriptional repressor 1	Homo sapiens	99-104
26741501-9	2016	As a result, oroxylin A up-regulated E-cadherin expression and down-regulated vimentin, MMP-9, and CD44v6 expression, which could lead to the inhibition of tumor migration and invasion.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cadherin 1	Homo sapiens	37-47
26741501-9	2016	As a result, oroxylin A up-regulated E-cadherin expression and down-regulated vimentin, MMP-9, and CD44v6 expression, which could lead to the inhibition of tumor migration and invasion.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	vimentin	Homo sapiens	78-86
26741501-9	2016	As a result, oroxylin A up-regulated E-cadherin expression and down-regulated vimentin, MMP-9, and CD44v6 expression, which could lead to the inhibition of tumor migration and invasion.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	matrix metallopeptidase 9	Homo sapiens	88-93
26741501-10	2016	Mechanically, we demonstrated that oroxylin A suppressed activation of ERK instead of AKT pathway and then promoted activation of GSK-3beta to reduce Snail protein content.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	mitogen-activated protein kinase 1	Homo sapiens	71-74
26741501-10	2016	Mechanically, we demonstrated that oroxylin A suppressed activation of ERK instead of AKT pathway and then promoted activation of GSK-3beta to reduce Snail protein content.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	AKT serine/threonine kinase 1	Homo sapiens	86-89
26741501-10	2016	Mechanically, we demonstrated that oroxylin A suppressed activation of ERK instead of AKT pathway and then promoted activation of GSK-3beta to reduce Snail protein content.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	glycogen synthase kinase 3 beta	Homo sapiens	130-139
26741501-10	2016	Mechanically, we demonstrated that oroxylin A suppressed activation of ERK instead of AKT pathway and then promoted activation of GSK-3beta to reduce Snail protein content.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	snail family transcriptional repressor 1	Homo sapiens	150-155
26741501-0	2016	Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3beta signaling in snail-expressing non-small-cell lung cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen-activated protein kinase 1	Homo sapiens	63-66
26741501-0	2016	Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3beta signaling in snail-expressing non-small-cell lung cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	glycogen synthase kinase 3 beta	Homo sapiens	67-76
26741501-0	2016	Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3beta signaling in snail-expressing non-small-cell lung cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	snail family transcriptional repressor 1	Homo sapiens	90-95
26741501-5	2016	The results suggested that oroxylin A could inhibit migration and invasion in Snail-expressing 95-D, and A549 cells whereas it had little effect on non-expressing GLC-82 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	snail family transcriptional repressor 1	Homo sapiens	78-83
26741501-6	2016	Furthermore, enhanced Snail expression after transfection of Snail vector in GLC-82 cells is decreased by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	106-116	snail family transcriptional repressor 1	Homo sapiens	22-27
26741501-6	2016	Furthermore, enhanced Snail expression after transfection of Snail vector in GLC-82 cells is decreased by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	106-116	snail family transcriptional repressor 1	Homo sapiens	61-66
26741501-8	2016	We found oroxylin A could reverse TGFbeta1-induced epithelial-mesenchymal transition by inhibiting Snail expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	transforming growth factor beta 1	Homo sapiens	34-42
27634872-8	2016	In vitro incubation of the ALDH2 activator Alda-1, the Sirt3 activator oroxylin A and the histone acetyltransferase inhibitor CPTH2 rescued insulin resistance-induced changes in aconitase activity and cardiomyocyte function (p < 0.05).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	71-81	sirtuin 3	Mus musculus	55-60
27764743-6	2016	In vivo, the results showed that oroxylin A dose-dependently attenuated CS-induced lung histopathologic changes, expression of cytokines TNF-alpha, IL-1beta, and MCP-1, and levels of oxidative biomarkers 3-nitrotyrosine and 8-isoprostane.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	tumor necrosis factor	Mus musculus	137-146
27764743-6	2016	In vivo, the results showed that oroxylin A dose-dependently attenuated CS-induced lung histopathologic changes, expression of cytokines TNF-alpha, IL-1beta, and MCP-1, and levels of oxidative biomarkers 3-nitrotyrosine and 8-isoprostane.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	interleukin 1 beta	Mus musculus	148-156
27764743-6	2016	In vivo, the results showed that oroxylin A dose-dependently attenuated CS-induced lung histopathologic changes, expression of cytokines TNF-alpha, IL-1beta, and MCP-1, and levels of oxidative biomarkers 3-nitrotyrosine and 8-isoprostane.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	mast cell protease 1	Mus musculus	162-167
27764743-7	2016	Meanwhile, oroxylin A up-regulated GSH level and glutathione reductase (GR) activity in lung tissues.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	11-21	glutathione reductase	Mus musculus	49-70
27764743-7	2016	Meanwhile, oroxylin A up-regulated GSH level and glutathione reductase (GR) activity in lung tissues.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	11-21	glutathione reductase	Mus musculus	72-74
27764743-8	2016	In vitro, oroxylin A significantly up-regulated Nrf2 expression and total cellular glutathione level in cigarette smoke extract (CSE)-stimulated cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	48-52
27764743-9	2016	In addition, oroxylin A promoted Nrf2 binding to antioxidant response element (ARE) and up-regulated ARE-regulated gene such as heme oxygenase-1 (HO-1), GPx, and GR in CSE-stimulated cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	33-37
27764743-9	2016	In addition, oroxylin A promoted Nrf2 binding to antioxidant response element (ARE) and up-regulated ARE-regulated gene such as heme oxygenase-1 (HO-1), GPx, and GR in CSE-stimulated cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	heme oxygenase 1	Mus musculus	128-144
27764743-9	2016	In addition, oroxylin A promoted Nrf2 binding to antioxidant response element (ARE) and up-regulated ARE-regulated gene such as heme oxygenase-1 (HO-1), GPx, and GR in CSE-stimulated cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	peroxiredoxin 6 pseudogene 2	Mus musculus	153-156
27764743-9	2016	In addition, oroxylin A promoted Nrf2 binding to antioxidant response element (ARE) and up-regulated ARE-regulated gene such as heme oxygenase-1 (HO-1), GPx, and GR in CSE-stimulated cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	glutathione reductase	Mus musculus	162-164
27764743-11	2016	Taken together, these data indicated that oroxylin A attenuated oxidative stress and lung inflammation induced by CS via activating Nrf2 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	nuclear factor, erythroid derived 2, like 2	Mus musculus	132-136
25213258-0	2015	Oroxylin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mechanistic target of rapamycin kinase	Homo sapiens	69-73
26259145-4	2016	Moreover, oroxylin A inhibited HIF-1alpha expression and its stability.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	hypoxia inducible factor 1 subunit alpha	Homo sapiens	31-41
26259145-5	2016	The downstream targets (PDK1, LDHA, and HK II), as well as their mRNA levels were also suppressed by oroxylin A under hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	101-111	pyruvate dehydrogenase kinase 1	Homo sapiens	24-28
26259145-5	2016	The downstream targets (PDK1, LDHA, and HK II), as well as their mRNA levels were also suppressed by oroxylin A under hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	101-111	lactate dehydrogenase A	Homo sapiens	30-34
26259145-5	2016	The downstream targets (PDK1, LDHA, and HK II), as well as their mRNA levels were also suppressed by oroxylin A under hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	101-111	hexokinase 2	Homo sapiens	40-45
26259145-6	2016	The silencing or the overexpression of HIF-1alpha assays suggested that HIF-1alpha is required for metabolic effect of oroxylin A in HepG2 cells during hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	119-129	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49
26259145-6	2016	The silencing or the overexpression of HIF-1alpha assays suggested that HIF-1alpha is required for metabolic effect of oroxylin A in HepG2 cells during hypoxia.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	119-129	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-82
26895180-0	2016	Oroxylin A Inhibits Allergic Airway Inflammation in Ovalbumin (OVA)-Induced Asthma Murine Model.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	52-61
26895180-0	2016	Oroxylin A Inhibits Allergic Airway Inflammation in Ovalbumin (OVA)-Induced Asthma Murine Model.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	63-66
26895180-2	2016	In this study, we aimed to investigate the protective effects and mechanism of oroxylin A on allergic inflammation in OVA-induced asthma murine model.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	79-89	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	118-121
26895180-5	2016	The results showed that oroxylin A attenuated OVA-induced lung histopathologic changes, airway hyperresponsiveness, and the number of inflammatory cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	46-49
26895180-6	2016	Oroxylin A also inhibited the levels of IL-4, IL-5, IL-13, and OVA-specific IgE in BALF.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 4	Mus musculus	40-44
26895180-6	2016	Oroxylin A also inhibited the levels of IL-4, IL-5, IL-13, and OVA-specific IgE in BALF.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 5	Mus musculus	46-50
26895180-6	2016	Oroxylin A also inhibited the levels of IL-4, IL-5, IL-13, and OVA-specific IgE in BALF.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 13	Mus musculus	52-57
26895180-6	2016	Oroxylin A also inhibited the levels of IL-4, IL-5, IL-13, and OVA-specific IgE in BALF.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	63-66
26895180-7	2016	Furthermore, oroxylin A significantly inhibited OVA-induced NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	48-51
26895180-8	2016	In conclusion, these results suggested that oroxylin A inhibited airway inflammation in OVA-induced asthma murine model by inhibiting NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	88-91
26958937-0	2016	Oroxylin A modulates mitochondrial function and apoptosis in human colon cancer cells by inducing mitochondrial translocation of wild-type p53.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	139-142
26958937-5	2016	We determined that oroxylin A induces p53 mitochondrial translocation and inhibits SOD2 activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	tumor protein p53	Homo sapiens	38-41
26958937-5	2016	We determined that oroxylin A induces p53 mitochondrial translocation and inhibits SOD2 activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	superoxide dismutase 2	Homo sapiens	83-87
26958937-6	2016	Additionally, our studies demonstrate that oroxylin A promotes the formation and mitochondrial translocation of the p53-Recql4 complex in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	tumor protein p53	Homo sapiens	116-119
26958937-6	2016	Additionally, our studies demonstrate that oroxylin A promotes the formation and mitochondrial translocation of the p53-Recql4 complex in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	RecQ like helicase 4	Homo sapiens	120-126
26958937-7	2016	Finally, we showed that oroxylin A triggers cytosolic p53 activation, thereby promoting apoptosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	tumor protein p53	Homo sapiens	54-57
26958937-9	2016	Thus, oroxylin A induces mitochondrial translocation of p53 and leads to mitochondrial dysfunction in human colon cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	6-16	tumor protein p53	Homo sapiens	56-59
27195463-4	2016	Importantly, treatment of mice with oroxylin A reduced viral titers in the pancreas and decreased the serum levels of the inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	interleukin 6	Mus musculus	155-168
27195463-4	2016	Importantly, treatment of mice with oroxylin A reduced viral titers in the pancreas and decreased the serum levels of the inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	interleukin 6	Mus musculus	170-174
27195463-4	2016	Importantly, treatment of mice with oroxylin A reduced viral titers in the pancreas and decreased the serum levels of the inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	tumor necrosis factor	Mus musculus	180-213
26512996-7	2016	The cell counting kit-8 assay demonstrated that wogonin, oroxylin A and chrysin showed high inhibitory activities in a dose-dependent manner on HepG2 cells at the concentration of 12.5-200 muM (p<0.05) and the IC50 values were 69.83, 16.66 and 51.6 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	57-67	latexin	Homo sapiens	189-192
26512996-7	2016	The cell counting kit-8 assay demonstrated that wogonin, oroxylin A and chrysin showed high inhibitory activities in a dose-dependent manner on HepG2 cells at the concentration of 12.5-200 muM (p<0.05) and the IC50 values were 69.83, 16.66 and 51.6 muM, respectively.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	57-67	latexin	Homo sapiens	252-255
25213258-10	2015	3-MA (autophagy inhibitor) or knockdown of Beclin 1 partially can rescue cells from oroxylin A-induced autophagic cell death.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	84-94	beclin 1	Homo sapiens	43-51
25213258-11	2015	In contrast, knockdown of STAT3 aggravates oroxylin A-induced autophagic cell death.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	signal transducer and activator of transcription 3	Homo sapiens	26-31
25213258-12	2015	Our data reveal an important role of autophagy in enhancing cell death induced by oroxylin A and conclude that oroxylin A exerts anti-malignant glioma proficiency by inducing autophagy via the ERK/AKT-mTOR-STAT3-Notch signaling cascade.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	mitogen-activated protein kinase 1	Homo sapiens	193-196
25213258-12	2015	Our data reveal an important role of autophagy in enhancing cell death induced by oroxylin A and conclude that oroxylin A exerts anti-malignant glioma proficiency by inducing autophagy via the ERK/AKT-mTOR-STAT3-Notch signaling cascade.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	AKT serine/threonine kinase 1	Homo sapiens	197-200
25213258-12	2015	Our data reveal an important role of autophagy in enhancing cell death induced by oroxylin A and conclude that oroxylin A exerts anti-malignant glioma proficiency by inducing autophagy via the ERK/AKT-mTOR-STAT3-Notch signaling cascade.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	mechanistic target of rapamycin kinase	Homo sapiens	201-205
25213258-12	2015	Our data reveal an important role of autophagy in enhancing cell death induced by oroxylin A and conclude that oroxylin A exerts anti-malignant glioma proficiency by inducing autophagy via the ERK/AKT-mTOR-STAT3-Notch signaling cascade.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	signal transducer and activator of transcription 3	Homo sapiens	206-211
25213258-12	2015	Our data reveal an important role of autophagy in enhancing cell death induced by oroxylin A and conclude that oroxylin A exerts anti-malignant glioma proficiency by inducing autophagy via the ERK/AKT-mTOR-STAT3-Notch signaling cascade.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	notch receptor 1	Homo sapiens	212-217
25213258-0	2015	Oroxylin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	signal transducer and activator of transcription 3	Homo sapiens	74-79
25213258-0	2015	Oroxylin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	notch receptor 1	Homo sapiens	80-85
25213258-8	2015	Oroxylin A treatment inhibits the AKT and ERK activation and the downstream phosphorylation level of mTOR and STAT3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	AKT serine/threonine kinase 1	Homo sapiens	34-37
25213258-8	2015	Oroxylin A treatment inhibits the AKT and ERK activation and the downstream phosphorylation level of mTOR and STAT3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen-activated protein kinase 1	Homo sapiens	42-45
25213258-8	2015	Oroxylin A treatment inhibits the AKT and ERK activation and the downstream phosphorylation level of mTOR and STAT3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mechanistic target of rapamycin kinase	Homo sapiens	101-105
25213258-8	2015	Oroxylin A treatment inhibits the AKT and ERK activation and the downstream phosphorylation level of mTOR and STAT3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	signal transducer and activator of transcription 3	Homo sapiens	110-115
25213258-9	2015	In addition, oroxylin A treatment decreases the expression of Notch-1 and myeloid cell leukemia-1 (Mcl-1) but upregulates Beclin 1, the key autophagy-related protein.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	notch receptor 1	Homo sapiens	62-69
25213258-9	2015	In addition, oroxylin A treatment decreases the expression of Notch-1 and myeloid cell leukemia-1 (Mcl-1) but upregulates Beclin 1, the key autophagy-related protein.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	74-97
25213258-9	2015	In addition, oroxylin A treatment decreases the expression of Notch-1 and myeloid cell leukemia-1 (Mcl-1) but upregulates Beclin 1, the key autophagy-related protein.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	99-104
25213258-9	2015	In addition, oroxylin A treatment decreases the expression of Notch-1 and myeloid cell leukemia-1 (Mcl-1) but upregulates Beclin 1, the key autophagy-related protein.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	beclin 1	Homo sapiens	122-130
26096700-6	2015	Furthermore, oroxylin A and tectorigenin potently inhibited LPS/CHX-induced phosphorylation of phosphoinositide 3-kinase (PI3K), pyruvate dehydrogenase lipoamide kinase isozyme 1, Akt, and glycogen synthase kinase-3beta in the Tat-transduced cells, D3-transfected CHME5 cells, and D3-infected human primary macrophages.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	95-120
26096700-6	2015	Furthermore, oroxylin A and tectorigenin potently inhibited LPS/CHX-induced phosphorylation of phosphoinositide 3-kinase (PI3K), pyruvate dehydrogenase lipoamide kinase isozyme 1, Akt, and glycogen synthase kinase-3beta in the Tat-transduced cells, D3-transfected CHME5 cells, and D3-infected human primary macrophages.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	AKT serine/threonine kinase 1	Homo sapiens	129-219
25192658-0	2014	Oroxylin A inhibits ATRA-induced IL-6 expression involved in retinoic acid syndrome by down-regulating CHOP.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 6	Homo sapiens	33-37
25818981-7	2015	RESULTS: The results showed that oroxylin A dose-dependently inhibited LPS and/or GalN-induced serum alanine aminotransferase, aspartate aminotransferase, and tumor necrosis factor-alpha levels.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	galanin and GMAP prepropeptide	Mus musculus	82-86
25818981-7	2015	RESULTS: The results showed that oroxylin A dose-dependently inhibited LPS and/or GalN-induced serum alanine aminotransferase, aspartate aminotransferase, and tumor necrosis factor-alpha levels.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	tumor necrosis factor	Mus musculus	127-186
25818981-9	2015	We also found that oroxylin A inhibited LPS and/or GalN-induced toll like receptor 4 (TLR4) expression and NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	galanin and GMAP prepropeptide	Mus musculus	51-55
25818981-9	2015	We also found that oroxylin A inhibited LPS and/or GalN-induced toll like receptor 4 (TLR4) expression and NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	toll-like receptor 4	Mus musculus	86-90
25818981-9	2015	We also found that oroxylin A inhibited LPS and/or GalN-induced toll like receptor 4 (TLR4) expression and NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-116
25818981-10	2015	In addition, oroxylin A upregulated the expression of Nrf2 and HO-1 in a dose-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	54-58
25818981-10	2015	In addition, oroxylin A upregulated the expression of Nrf2 and HO-1 in a dose-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	heme oxygenase 1	Mus musculus	63-67
25818981-11	2015	CONCLUSIONS: In conclusion, oroxylin A protected against LPS and/or GalN-induced liver injury through activating Nrf2 and inhibiting TLR4 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	galanin and GMAP prepropeptide	Mus musculus	68-72
25818981-11	2015	CONCLUSIONS: In conclusion, oroxylin A protected against LPS and/or GalN-induced liver injury through activating Nrf2 and inhibiting TLR4 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	nuclear factor, erythroid derived 2, like 2	Mus musculus	113-117
25818981-11	2015	CONCLUSIONS: In conclusion, oroxylin A protected against LPS and/or GalN-induced liver injury through activating Nrf2 and inhibiting TLR4 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	toll-like receptor 4	Mus musculus	133-137
25251374-0	2015	UCP2-related mitochondrial pathway participates in oroxylin A-induced apoptosis in human colon cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	51-61	uncoupling protein 2	Homo sapiens	0-4
25251374-3	2015	This paper explores the mechanism how oroxylin A induce apoptosis by regulating uncoupling protein 2 (UCP2) in human colon cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	uncoupling protein 2	Homo sapiens	80-100
25251374-3	2015	This paper explores the mechanism how oroxylin A induce apoptosis by regulating uncoupling protein 2 (UCP2) in human colon cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	uncoupling protein 2	Homo sapiens	102-106
25251374-6	2015	Furthermore, we demonstrated that oroxylin A triggered MPTP-dependent pro-apoptotic protein release from mitochondria to matrix and then induced apoptotic cascade by inhibiting UCP2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	34-44	uncoupling protein 2	Homo sapiens	177-181
25251374-7	2015	Intriguingly, the inhibition of UCP2 by oroxylin A was able to block Bcl-2 translocation to the mitochondria, keeping MPTP at open-state.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	uncoupling protein 2	Homo sapiens	32-36
25251374-7	2015	Intriguingly, the inhibition of UCP2 by oroxylin A was able to block Bcl-2 translocation to the mitochondria, keeping MPTP at open-state.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	BCL2 apoptosis regulator	Homo sapiens	69-74
25251374-8	2015	In conclusion, we have demonstrated that UCP2 plays a key role in mitochondrial apoptotic pathway; UCP2s inhibition by oroxylin A triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	119-129	uncoupling protein 2	Homo sapiens	99-103
25855962-0	2015	Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1alpha destabilization.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	sirtuin 3	Homo sapiens	92-97
25855962-0	2015	Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1alpha destabilization.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	superoxide dismutase 2	Homo sapiens	107-111
25855962-0	2015	Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1alpha destabilization.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	130-139
24671465-0	2015	Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	93-103	signal transducer and activator of transcription 3	Homo sapiens	143-148
24671465-7	2015	After treatment of weakly toxic concentration of oroxylin A, the apoptosis of K562 cells induced by IM was increased dramatically through suppressing Stat3 pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	49-59	signal transducer and activator of transcription 3	Homo sapiens	150-155
24671465-8	2015	In addition, the in vivo study showed that oroxylin A potentiates the inhibitory effects of IM on leukemia development by suppressing Stat3 pathway in the K562 xenograft model.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	signal transducer and activator of transcription 3	Homo sapiens	134-139
24671465-10	2015	Additionally, oroxylin A improved the sensitivity of K562 cells to IM in SFM-DR model and in vivo, and the underlying mechanism attributed to the suppression of Stat3 pathway, which suggested oroxylin A might be a promising agent for treatment designed to eradicate MRD in CML patients.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	192-202	signal transducer and activator of transcription 3	Homo sapiens	161-166
25577335-7	2015	Combination of baicalein (20 mug/ml), oroxylin A (8 mug/ml), and wogonin (2 mug/ml) markedly inhibits TNF-alpha-induced COX-2 expression when compared with individual components.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	tumor necrosis factor	Mus musculus	102-111
25577335-7	2015	Combination of baicalein (20 mug/ml), oroxylin A (8 mug/ml), and wogonin (2 mug/ml) markedly inhibits TNF-alpha-induced COX-2 expression when compared with individual components.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	cytochrome c oxidase II, mitochondrial	Mus musculus	120-125
25902914-0	2015	Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	phosphatase and tensin homolog	Homo sapiens	20-24
25902914-0	2015	Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	MDM2 proto-oncogene	Homo sapiens	57-61
25902914-0	2015	Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	sirtuin 3	Homo sapiens	80-85
25902914-0	2015	Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	122-125
25902914-0	2015	Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	155-158
25902914-9	2015	RESULTS: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	tumor protein p53	Homo sapiens	79-82
25902914-9	2015	RESULTS: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	tumor protein p53	Homo sapiens	121-124
25902914-9	2015	RESULTS: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	58-68	tumor protein p53	Homo sapiens	121-124
25902914-9	2015	RESULTS: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	154-164	tumor protein p53	Homo sapiens	79-82
25902914-9	2015	RESULTS: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	154-164	tumor protein p53	Homo sapiens	121-124
25902914-9	2015	RESULTS: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	154-164	tumor protein p53	Homo sapiens	121-124
25902914-10	2015	Oroxylin A did not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	MDM2 proto-oncogene	Homo sapiens	83-87
25902914-10	2015	Oroxylin A did not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	112-115
25902914-10	2015	Oroxylin A did not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	MDM2 proto-oncogene	Homo sapiens	135-139
25902914-10	2015	Oroxylin A did not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	112-115
25902914-11	2015	In further studies, we found that oroxylin A induced a reduction in MDM2 transcription by promoting the lipid phosphatase activity of phosphatase and tensin homolog, which was upregulated via sirtuin3-mediated deacetylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	34-44	MDM2 proto-oncogene	Homo sapiens	68-72
25902914-13	2015	The expression of MDM2 protein in tumor tissue was downregulated by oroxylin A as well.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	MDM2 proto-oncogene	Homo sapiens	18-22
25902914-14	2015	CONCLUSIONS: These results provide a p53-independent mechanism of MDM2 transcription and reveal the potential of oroxylin A on glycolytic regulation in both wt-p53 and mut-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	113-123	tumor protein p53	Homo sapiens	160-163
25902914-14	2015	CONCLUSIONS: These results provide a p53-independent mechanism of MDM2 transcription and reveal the potential of oroxylin A on glycolytic regulation in both wt-p53 and mut-p53 cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	113-123	tumor protein p53	Homo sapiens	160-163
25855962-4	2015	Here, we show that oroxylin A inhibits glycolysis in breast cancer cells via the Sirtuin 3 (SIRT3)-mediated destabilization of hypoxia-inducible factor 1alpha (HIF1alpha), which controls glycolytic gene expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	sirtuin 3	Homo sapiens	81-90
25855962-4	2015	Here, we show that oroxylin A inhibits glycolysis in breast cancer cells via the Sirtuin 3 (SIRT3)-mediated destabilization of hypoxia-inducible factor 1alpha (HIF1alpha), which controls glycolytic gene expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	sirtuin 3	Homo sapiens	92-97
25855962-4	2015	Here, we show that oroxylin A inhibits glycolysis in breast cancer cells via the Sirtuin 3 (SIRT3)-mediated destabilization of hypoxia-inducible factor 1alpha (HIF1alpha), which controls glycolytic gene expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	hypoxia inducible factor 1 subunit alpha	Homo sapiens	127-158
25855962-4	2015	Here, we show that oroxylin A inhibits glycolysis in breast cancer cells via the Sirtuin 3 (SIRT3)-mediated destabilization of hypoxia-inducible factor 1alpha (HIF1alpha), which controls glycolytic gene expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	19-29	hypoxia inducible factor 1 subunit alpha	Homo sapiens	160-169
25855962-5	2015	Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	superoxide dismutase 2	Homo sapiens	42-46
25855962-5	2015	Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	sirtuin 3	Homo sapiens	72-77
25855962-5	2015	Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	forkhead box O3	Homo sapiens	112-118
25855962-5	2015	Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	superoxide dismutase 2	Homo sapiens	149-153
25855962-5	2015	Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	sirtuin 3	Homo sapiens	167-172
25855962-7	2015	These data indicate that oroxylin A inhibits glycolysis-dependent proliferation of breast cancer cells, through the suppression of HIF1alpha stabilization via SIRT3 activation, providing preclinical information for the cancer therapies of SIRT3 stimulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	131-140
25855962-7	2015	These data indicate that oroxylin A inhibits glycolysis-dependent proliferation of breast cancer cells, through the suppression of HIF1alpha stabilization via SIRT3 activation, providing preclinical information for the cancer therapies of SIRT3 stimulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	sirtuin 3	Homo sapiens	159-164
25855962-7	2015	These data indicate that oroxylin A inhibits glycolysis-dependent proliferation of breast cancer cells, through the suppression of HIF1alpha stabilization via SIRT3 activation, providing preclinical information for the cancer therapies of SIRT3 stimulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	sirtuin 3	Homo sapiens	239-244
25192658-0	2014	Oroxylin A inhibits ATRA-induced IL-6 expression involved in retinoic acid syndrome by down-regulating CHOP.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	DNA damage inducible transcript 3	Homo sapiens	103-107
25192658-5	2014	Oroxylin A has been reported to activate CHOP, a key mediator of unfolded protein response (UPR) pathway, and resulted in apoptosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	DNA damage inducible transcript 3	Homo sapiens	41-45
25192658-6	2014	Interestingly, we found that low concentration of oroxylin A (  40 muM) showed no apoptosis effect on NB4 and HL-60 cells and decreased the CHOP protein level via promoting its degradation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	50-60	DNA damage inducible transcript 3	Homo sapiens	140-144
25192658-7	2014	MG132 was utilized to conform the effect of oroxylin A on degrading CHOP.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	44-54	DNA damage inducible transcript 3	Homo sapiens	68-72
25192658-8	2014	Our results showed that oroxylin A decreased the level of IL-6 secretion of NB4 cells with or without ATRA treatment while the effect was eliminated by C/EBPbeta siRNA.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	interleukin 6	Homo sapiens	58-62
25192658-8	2014	Our results showed that oroxylin A decreased the level of IL-6 secretion of NB4 cells with or without ATRA treatment while the effect was eliminated by C/EBPbeta siRNA.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	CCAAT enhancer binding protein beta	Homo sapiens	152-161
25192658-9	2014	We conclude that oroxylin A possessed abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	interleukin 6	Homo sapiens	79-83
25192658-9	2014	We conclude that oroxylin A possessed abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	LAP	Homo sapiens	113-116
25192658-9	2014	We conclude that oroxylin A possessed abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	DNA damage inducible transcript 3	Homo sapiens	121-125
22949302-4	2014	The results indicated that treatment with oroxylin A inhibited NF-kappaB p65 nuclear translocation and phosphorylation of IkappaBalpha and IKKalpha/beta in both human colon tumor HCT116 cells and human monocytes THP-1 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	RELA proto-oncogene, NF-kB subunit	Homo sapiens	73-76
25218897-7	2014	Blocking mBDNF signaling with recombinant tropomyosin receptor kinase B (TrkB)-Fc or k252a at 9h after the acquisition trial obstructed the effect of oroxylin A on memory consolidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	150-160	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	73-77
25218897-8	2014	Taken together, our data suggest that oroxylin A facilitates memory consolidation through BDNF-TrkB signaling and confirms that the increase of BDNF in a specific time window plays a crucial role in memory consolidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	brain derived neurotrophic factor	Mus musculus	90-94
25218897-8	2014	Taken together, our data suggest that oroxylin A facilitates memory consolidation through BDNF-TrkB signaling and confirms that the increase of BDNF in a specific time window plays a crucial role in memory consolidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	95-99
25218897-8	2014	Taken together, our data suggest that oroxylin A facilitates memory consolidation through BDNF-TrkB signaling and confirms that the increase of BDNF in a specific time window plays a crucial role in memory consolidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	brain derived neurotrophic factor	Mus musculus	144-148
24858801-4	2014	Moreover, the sensitivity enhancement of oroxylin A was demonstrated by decreasing the expression of CXCR4 at both protein and mRNA levels, via PI3K/Akt/NF-kappaB pathway and triggering the apoptosis pathway in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	41-51	C-X-C motif chemokine receptor 4	Homo sapiens	101-106
24858801-4	2014	Moreover, the sensitivity enhancement of oroxylin A was demonstrated by decreasing the expression of CXCR4 at both protein and mRNA levels, via PI3K/Akt/NF-kappaB pathway and triggering the apoptosis pathway in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	41-51	AKT serine/threonine kinase 1	Homo sapiens	149-152
24858801-4	2014	Moreover, the sensitivity enhancement of oroxylin A was demonstrated by decreasing the expression of CXCR4 at both protein and mRNA levels, via PI3K/Akt/NF-kappaB pathway and triggering the apoptosis pathway in vitro.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	41-51	nuclear factor kappa B subunit 1	Homo sapiens	153-162
24858801-6	2014	In conclusion, all these results showed that oroxylin A improved the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-kappaB pathway, and probably served as a most promising agent for CML treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	C-X-C motif chemokine receptor 4	Homo sapiens	174-179
24858801-6	2014	In conclusion, all these results showed that oroxylin A improved the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-kappaB pathway, and probably served as a most promising agent for CML treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	AKT serine/threonine kinase 1	Homo sapiens	189-192
24858801-6	2014	In conclusion, all these results showed that oroxylin A improved the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-kappaB pathway, and probably served as a most promising agent for CML treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	nuclear factor kappa B subunit 1	Homo sapiens	193-202
25247252-0	2014	Oroxylin A exerts anti-inflammatory activity on lipopolysaccharide-induced mouse macrophage via Nrf2/ARE activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	96-100
25247252-3	2014	The results demonstrate that pretreatment with oroxylin A (50, 100, and 150 mumol/L) inhibited lipopolysaccharide (LPS)-induced mRNA and protein expression of COX-2 and iNOS.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	47-57	cytochrome c oxidase II, mitochondrial	Mus musculus	159-164
25247252-3	2014	The results demonstrate that pretreatment with oroxylin A (50, 100, and 150 mumol/L) inhibited lipopolysaccharide (LPS)-induced mRNA and protein expression of COX-2 and iNOS.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	47-57	nitric oxide synthase 2, inducible	Mus musculus	169-173
25247252-4	2014	In addition, oroxylin A significantly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NADP(H):quinone oxidoreductase (NQO1), induced Nrf2 translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	74-117
25247252-4	2014	In addition, oroxylin A significantly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NADP(H):quinone oxidoreductase (NQO1), induced Nrf2 translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	119-123
25247252-4	2014	In addition, oroxylin A significantly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NADP(H):quinone oxidoreductase (NQO1), induced Nrf2 translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	heme oxygenase 1	Mus musculus	126-142
25247252-4	2014	In addition, oroxylin A significantly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NADP(H):quinone oxidoreductase (NQO1), induced Nrf2 translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	heme oxygenase 1	Mus musculus	144-148
25247252-4	2014	In addition, oroxylin A significantly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NADP(H):quinone oxidoreductase (NQO1), induced Nrf2 translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	NAD(P)H dehydrogenase, quinone 1	Mus musculus	187-191
25247252-4	2014	In addition, oroxylin A significantly increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NADP(H):quinone oxidoreductase (NQO1), induced Nrf2 translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	202-206
25247252-5	2014	Moreover, oroxylin A inhibited Nrf2 ubiquitination and proteasome activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	31-35
25247252-6	2014	Transfection with Nrf2 siRNA knocked down Nrf2 expression and partially reversed oroxylin A-mediated inhibition of LPS-induced COX-2 and iNOS expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	81-91	nuclear factor, erythroid derived 2, like 2	Mus musculus	18-22
25247252-6	2014	Transfection with Nrf2 siRNA knocked down Nrf2 expression and partially reversed oroxylin A-mediated inhibition of LPS-induced COX-2 and iNOS expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	81-91	cytochrome c oxidase II, mitochondrial	Mus musculus	127-132
25247252-6	2014	Transfection with Nrf2 siRNA knocked down Nrf2 expression and partially reversed oroxylin A-mediated inhibition of LPS-induced COX-2 and iNOS expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	81-91	nitric oxide synthase 2, inducible	Mus musculus	137-141
25247252-7	2014	Importantly, we showed for the first time that Nrf2 plays an important role in oroxylin A-suppressed inflammation in RAW264.7 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	79-89	nuclear factor, erythroid derived 2, like 2	Mus musculus	47-51
25247252-8	2014	Uncovering the effect of oroxylin A on the regulation of Nrf2 signaling may be beneficial for developing new therapeutic strategies against inflammatory diseases.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	nuclear factor, erythroid derived 2, like 2	Mus musculus	57-61
25218897-0	2014	Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	brain derived neurotrophic factor	Mus musculus	53-86
25218897-4	2014	Oroxylin A increased mature brain-derived neurotrophic factor (mBDNF) levels in the hippocampus from 6h to 24h after administration.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	brain derived neurotrophic factor	Mus musculus	28-61
25218897-4	2014	Oroxylin A increased mature brain-derived neurotrophic factor (mBDNF) levels in the hippocampus from 6h to 24h after administration.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	brain derived neurotrophic factor	Mus musculus	63-68
25218897-5	2014	Moreover, 3h post-training administration of oroxylin A enhanced the mBDNF level at 9h after the acquisition trial compared to the level at 6h after the acquisition trial.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	45-55	brain derived neurotrophic factor	Mus musculus	69-74
25218897-7	2014	Blocking mBDNF signaling with recombinant tropomyosin receptor kinase B (TrkB)-Fc or k252a at 9h after the acquisition trial obstructed the effect of oroxylin A on memory consolidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	150-160	brain derived neurotrophic factor	Mus musculus	9-14
25218897-7	2014	Blocking mBDNF signaling with recombinant tropomyosin receptor kinase B (TrkB)-Fc or k252a at 9h after the acquisition trial obstructed the effect of oroxylin A on memory consolidation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	150-160	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	42-71
24637576-4	2014	To study the detailed mechanisms, studies were carried out on MCF-7 cells and it was found that oroxylin A could regulate the expression of related markers in MCF-7 cells including E-cadherin, N-cadherin, and Vimentin.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	96-106	cadherin 1	Homo sapiens	181-191
24637576-4	2014	To study the detailed mechanisms, studies were carried out on MCF-7 cells and it was found that oroxylin A could regulate the expression of related markers in MCF-7 cells including E-cadherin, N-cadherin, and Vimentin.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	96-106	cadherin 2	Homo sapiens	193-203
24637576-4	2014	To study the detailed mechanisms, studies were carried out on MCF-7 cells and it was found that oroxylin A could regulate the expression of related markers in MCF-7 cells including E-cadherin, N-cadherin, and Vimentin.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	96-106	vimentin	Homo sapiens	209-217
24637576-6	2014	Oroxylin A inhibited N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	snail family transcriptional repressor 1	Homo sapiens	134-139
23963976-1	2014	Here, the anticoagulant activities of oroxylin A (OroA), a major component of Scutellaria baicalensis Georgi, were examined by monitoring activated partial thromboplastin time (aPTT), prothrombin time (PT), and the activities of cell-based thrombin and activated factor X (FXa).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	coagulation factor II, thrombin	Homo sapiens	187-195
23963976-1	2014	Here, the anticoagulant activities of oroxylin A (OroA), a major component of Scutellaria baicalensis Georgi, were examined by monitoring activated partial thromboplastin time (aPTT), prothrombin time (PT), and the activities of cell-based thrombin and activated factor X (FXa).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	coagulation factor X	Homo sapiens	273-276
23934681-0	2014	Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARgamma and RXRalpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	93-102
23934681-0	2014	Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARgamma and RXRalpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	retinoid X receptor alpha	Homo sapiens	107-115
22949302-4	2014	The results indicated that treatment with oroxylin A inhibited NF-kappaB p65 nuclear translocation and phosphorylation of IkappaBalpha and IKKalpha/beta in both human colon tumor HCT116 cells and human monocytes THP-1 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	NFKB inhibitor alpha	Homo sapiens	122-134
22949302-4	2014	The results indicated that treatment with oroxylin A inhibited NF-kappaB p65 nuclear translocation and phosphorylation of IkappaBalpha and IKKalpha/beta in both human colon tumor HCT116 cells and human monocytes THP-1 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	139-152
22949302-5	2014	In addition, in THP-1 cells, oroxylin A significantly suppressed lipopolysaccharide (LPS)-induced secretion of prototypical proinflammatory cytokine IL-6 but not IL-1beta, and it was confirmed at the transcription level.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	interleukin 6	Homo sapiens	149-153
23951204-5	2013	The data indicated that the IL-6 and TNF-alpha mRNA of oroxylin A administered group significantly increased higher than the control within 12 hours after CCl4 treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	interleukin 6	Mus musculus	28-32
24312202-6	2013	In this study, we found that three natural compounds, Oroxylin A 7-O-glucuronide (OLG), Oroxin A (ORA), and Oroxin B (ORB), when inhibiting the hemolytic activity of alpha-HL, could bind to the "stem" region of alpha-HL.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	54-64	AT695_RS11870	Staphylococcus aureus	166-174
24312202-6	2013	In this study, we found that three natural compounds, Oroxylin A 7-O-glucuronide (OLG), Oroxin A (ORA), and Oroxin B (ORB), when inhibiting the hemolytic activity of alpha-HL, could bind to the "stem" region of alpha-HL.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	54-64	AT695_RS11870	Staphylococcus aureus	211-219
23707903-3	2013	Among all oroxylin A analogs, compound 7-7 (5,7-dihydroxy-6-methoxy-4"-phenoxyflavone) showed the most remarkable inhibition of dopamine reuptake alike methylphenidate, a dopamine transporter (DAT) blocker and typical drug for ADHD, and oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	solute carrier family 6 member 3	Rattus norvegicus	171-191
23707903-3	2013	Among all oroxylin A analogs, compound 7-7 (5,7-dihydroxy-6-methoxy-4"-phenoxyflavone) showed the most remarkable inhibition of dopamine reuptake alike methylphenidate, a dopamine transporter (DAT) blocker and typical drug for ADHD, and oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	solute carrier family 6 member 3	Rattus norvegicus	193-196
23951204-5	2013	The data indicated that the IL-6 and TNF-alpha mRNA of oroxylin A administered group significantly increased higher than the control within 12 hours after CCl4 treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	tumor necrosis factor	Mus musculus	37-46
23951204-6	2013	Meanwhile, oroxylin A significantly enhanced the expression of IL-1Ra at the early phase, which indicated that oroxylin A could facilitate the initiating events in liver regeneration by increasing IL-1Ra which acts as an Acute-Phase Protein (APP).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	11-21	interleukin 1 receptor antagonist	Mus musculus	63-69
23951204-6	2013	Meanwhile, oroxylin A significantly enhanced the expression of IL-1Ra at the early phase, which indicated that oroxylin A could facilitate the initiating events in liver regeneration by increasing IL-1Ra which acts as an Acute-Phase Protein (APP).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	11-21	interleukin 1 receptor antagonist	Mus musculus	197-203
23951204-6	2013	Meanwhile, oroxylin A significantly enhanced the expression of IL-1Ra at the early phase, which indicated that oroxylin A could facilitate the initiating events in liver regeneration by increasing IL-1Ra which acts as an Acute-Phase Protein (APP).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	11-21	amyloid beta (A4) precursor protein	Mus musculus	221-240
23951204-6	2013	Meanwhile, oroxylin A significantly enhanced the expression of IL-1Ra at the early phase, which indicated that oroxylin A could facilitate the initiating events in liver regeneration by increasing IL-1Ra which acts as an Acute-Phase Protein (APP).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	interleukin 1 receptor antagonist	Mus musculus	63-69
23951204-6	2013	Meanwhile, oroxylin A significantly enhanced the expression of IL-1Ra at the early phase, which indicated that oroxylin A could facilitate the initiating events in liver regeneration by increasing IL-1Ra which acts as an Acute-Phase Protein (APP).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	interleukin 1 receptor antagonist	Mus musculus	197-203
23951204-6	2013	Meanwhile, oroxylin A significantly enhanced the expression of IL-1Ra at the early phase, which indicated that oroxylin A could facilitate the initiating events in liver regeneration by increasing IL-1Ra which acts as an Acute-Phase Protein (APP).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	111-121	amyloid beta (A4) precursor protein	Mus musculus	221-240
23951204-9	2013	CONCLUSIONS: Our study confirmed that oroxylin A could strongly promote liver structural remodeling and functional recovery through IL-1Ra/IL-1RI signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	interleukin 1 receptor antagonist	Mus musculus	132-138
23500080-8	2013	Oroxylin A sensitized A549 cells to anoikis by inactivating the c-Src/AKT/HK II pathway in addition to inducing the dissociation of HK II from mitochondria.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	thymoma viral proto-oncogene 1	Mus musculus	70-73
23823704-0	2013	Oroxylin A inhibits colitis-associated carcinogenesis through modulating the IL-6/STAT3 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	interleukin 6	Homo sapiens	77-81
23823704-0	2013	Oroxylin A inhibits colitis-associated carcinogenesis through modulating the IL-6/STAT3 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	signal transducer and activator of transcription 3	Homo sapiens	82-87
23823704-9	2013	RESULTS: Oroxylin A effectively inhibited IL-6/STAT3 pathway in human HCT-116 cells, and the effect of oroxylin A was reversible.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	interleukin 6	Homo sapiens	42-46
23823704-9	2013	RESULTS: Oroxylin A effectively inhibited IL-6/STAT3 pathway in human HCT-116 cells, and the effect of oroxylin A was reversible.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	signal transducer and activator of transcription 3	Homo sapiens	47-52
23823704-11	2013	The expression of inflammatory cytokines IL-6 and IL-1beta decreased in tumors in oroxylin A-treated mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	82-92	interleukin 6	Mus musculus	41-45
23823704-11	2013	The expression of inflammatory cytokines IL-6 and IL-1beta decreased in tumors in oroxylin A-treated mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	82-92	interleukin 1 beta	Mus musculus	50-58
23823704-12	2013	The IL-6/STAT3 signaling pathway was attenuated in oroxylin A-treated mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	51-61	interleukin 6	Mus musculus	4-8
23823704-12	2013	The IL-6/STAT3 signaling pathway was attenuated in oroxylin A-treated mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	51-61	signal transducer and activator of transcription 3	Mus musculus	9-14
23823704-13	2013	CONCLUSIONS: Our results demonstrated that oroxylin A inhibits colitis-associated carcinogenesis through modulating IL-6/STAT3 pathway in AOM/dextran sodium sulfate mouse model and in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	interleukin 6	Mus musculus	116-120
23823704-13	2013	CONCLUSIONS: Our results demonstrated that oroxylin A inhibits colitis-associated carcinogenesis through modulating IL-6/STAT3 pathway in AOM/dextran sodium sulfate mouse model and in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	signal transducer and activator of transcription 3	Mus musculus	121-126
23612020-0	2013	Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	tumor protein p53	Homo sapiens	4-7
23612020-0	2013	Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	TP53 induced glycolysis regulatory phosphatase	Homo sapiens	38-43
23612020-0	2013	Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	synthesis of cytochrome C oxidase 2	Homo sapiens	48-52
23612020-6	2013	Moreover, oroxylin A could increase protein and mRNA expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) and synthesis of cytochrome c oxidase 2 (SCO2), which are the key metabolic modulators regulated by p53.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	TP53 induced glycolysis regulatory phosphatase	Homo sapiens	67-114
23612020-6	2013	Moreover, oroxylin A could increase protein and mRNA expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) and synthesis of cytochrome c oxidase 2 (SCO2), which are the key metabolic modulators regulated by p53.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	TP53 induced glycolysis regulatory phosphatase	Homo sapiens	116-121
23612020-6	2013	Moreover, oroxylin A could increase protein and mRNA expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) and synthesis of cytochrome c oxidase 2 (SCO2), which are the key metabolic modulators regulated by p53.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	synthesis of cytochrome C oxidase 2	Homo sapiens	164-168
23612020-6	2013	Moreover, oroxylin A could increase protein and mRNA expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) and synthesis of cytochrome c oxidase 2 (SCO2), which are the key metabolic modulators regulated by p53.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	tumor protein p53	Homo sapiens	223-226
23612020-8	2013	Oroxylin A and adriamycin also modulated the stability and activity of p53 through inducing phosphorylation of p53 at Ser15 and suppressing the expression of MDM2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	71-74
23612020-8	2013	Oroxylin A and adriamycin also modulated the stability and activity of p53 through inducing phosphorylation of p53 at Ser15 and suppressing the expression of MDM2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	tumor protein p53	Homo sapiens	111-114
23612020-8	2013	Oroxylin A and adriamycin also modulated the stability and activity of p53 through inducing phosphorylation of p53 at Ser15 and suppressing the expression of MDM2.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	MDM2 proto-oncogene	Homo sapiens	158-162
23612020-9	2013	Furthermore, p53 siRNA and p53 inhibitor assay in wild-type p53 HepG2 cells both revealed the key role of p53 in oroxylin A and adriamycin-mediated glycolytic metabolism regulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	113-123	tumor protein p53	Homo sapiens	13-16
23612020-9	2013	Furthermore, p53 siRNA and p53 inhibitor assay in wild-type p53 HepG2 cells both revealed the key role of p53 in oroxylin A and adriamycin-mediated glycolytic metabolism regulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	113-123	tumor protein p53	Homo sapiens	27-30
23612020-9	2013	Furthermore, p53 siRNA and p53 inhibitor assay in wild-type p53 HepG2 cells both revealed the key role of p53 in oroxylin A and adriamycin-mediated glycolytic metabolism regulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	113-123	tumor protein p53	Homo sapiens	27-30
23612020-9	2013	Furthermore, p53 siRNA and p53 inhibitor assay in wild-type p53 HepG2 cells both revealed the key role of p53 in oroxylin A and adriamycin-mediated glycolytic metabolism regulation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	113-123	tumor protein p53	Homo sapiens	27-30
23612020-10	2013	Transfecting wt p53 plasmid to p53-deficient H1299 cells could inverse some of the metabolic characteristics regulated by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	122-132	tumor protein p53	Homo sapiens	16-19
23612020-10	2013	Transfecting wt p53 plasmid to p53-deficient H1299 cells could inverse some of the metabolic characteristics regulated by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	122-132	tumor protein p53	Homo sapiens	31-34
23500080-8	2013	Oroxylin A sensitized A549 cells to anoikis by inactivating the c-Src/AKT/HK II pathway in addition to inducing the dissociation of HK II from mitochondria.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hexokinase 2	Mus musculus	74-79
23500080-8	2013	Oroxylin A sensitized A549 cells to anoikis by inactivating the c-Src/AKT/HK II pathway in addition to inducing the dissociation of HK II from mitochondria.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hexokinase 2	Mus musculus	132-137
23500080-11	2013	CONCLUSIONS: Oroxylin A sensitized anoikis, which underlies distinct glucose-deprivation-like mechanisms that involved c-Src and HK II.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	hexokinase 2	Mus musculus	129-134
23598413-0	2013	Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	hexokinase 2	Homo sapiens	35-48
23470866-4	2013	After treatment with oroxylin A, MCF7/ADR cells displayed reduced functional activity and expression of MDR1 at both the protein and mRNA levels.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
23470866-5	2013	Meanwhile, oroxylin A induced cells G2/M arrest in a concentration-dependent manner by increasing the expression of p-Chk2 (Thr68).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	11-21	checkpoint kinase 2	Homo sapiens	118-122
23470866-7	2013	In conclusion, we suggested that oroxylin A reversed MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-kappaB signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	phosphoglycolate phosphatase	Homo sapiens	134-138
23470866-7	2013	In conclusion, we suggested that oroxylin A reversed MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-kappaB signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	checkpoint kinase 2	Homo sapiens	154-158
23470866-7	2013	In conclusion, we suggested that oroxylin A reversed MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-kappaB signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	tumor protein p53	Homo sapiens	159-162
23470866-7	2013	In conclusion, we suggested that oroxylin A reversed MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-kappaB signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-41	nuclear factor kappa B subunit 1	Homo sapiens	163-172
23598413-0	2013	Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	sirtuin 3	Homo sapiens	98-103
23598413-0	2013	Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	peptidylprolyl isomerase D	Homo sapiens	130-143
23598413-2	2013	We demonstrated that, Oroxylin A inhibited the glycolysis and the binding of hexokinase II (HK II) with mitochondria in human breast carcinoma cell lines, which was dependent on sirtuin-3 (SIRT3).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	hexokinase 2	Homo sapiens	77-90
23598413-2	2013	We demonstrated that, Oroxylin A inhibited the glycolysis and the binding of hexokinase II (HK II) with mitochondria in human breast carcinoma cell lines, which was dependent on sirtuin-3 (SIRT3).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	hexokinase 2	Homo sapiens	92-97
23598413-2	2013	We demonstrated that, Oroxylin A inhibited the glycolysis and the binding of hexokinase II (HK II) with mitochondria in human breast carcinoma cell lines, which was dependent on sirtuin-3 (SIRT3).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	sirtuin 3	Homo sapiens	178-187
23598413-2	2013	We demonstrated that, Oroxylin A inhibited the glycolysis and the binding of hexokinase II (HK II) with mitochondria in human breast carcinoma cell lines, which was dependent on sirtuin-3 (SIRT3).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	sirtuin 3	Homo sapiens	189-194
23598413-3	2013	The level of SIRT3 in mitochondria was increased by Oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	52-62	sirtuin 3	Homo sapiens	13-18
23598413-6	2013	These results have important implications for the metabolism reprogramming effect and the susceptibility to Oroxylin A-induced mitochondrial cytotoxicity through the regulation of SIRT3 in breast carcinoma.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	108-118	sirtuin 3	Homo sapiens	180-185
22906689-4	2012	Moreover, forced degradation studies were also carried out, and wogonin was shown to undergo isomerzation under basic stress condition to form a major degradant, 5,7-dihydroxy-6-methoxy-2-phenyl-4H-chromen-4-one (imp-2) using HPLC-Q-TOF-MS/MS technique.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	162-211	inositol monophosphatase 2	Homo sapiens	213-218
22607196-0	2012	Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	104-109
22607196-4	2012	A correlation between COX-2 inhibition by oroxylin A and a synergistic effect of 5-FU on the growth of HT-29 cells was observed, and a COX-2 pathway for this effect was recognized; oroxylin A evidently elevated the level of reactive oxygen species in HT-29 cells, which subsequently inhibited COX-2 expression and enhanced the susceptibility of HT-29 cells to 5-FU.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27
22607196-4	2012	A correlation between COX-2 inhibition by oroxylin A and a synergistic effect of 5-FU on the growth of HT-29 cells was observed, and a COX-2 pathway for this effect was recognized; oroxylin A evidently elevated the level of reactive oxygen species in HT-29 cells, which subsequently inhibited COX-2 expression and enhanced the susceptibility of HT-29 cells to 5-FU.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	181-191	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27
22607196-4	2012	A correlation between COX-2 inhibition by oroxylin A and a synergistic effect of 5-FU on the growth of HT-29 cells was observed, and a COX-2 pathway for this effect was recognized; oroxylin A evidently elevated the level of reactive oxygen species in HT-29 cells, which subsequently inhibited COX-2 expression and enhanced the susceptibility of HT-29 cells to 5-FU.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	181-191	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	135-140
22607196-4	2012	A correlation between COX-2 inhibition by oroxylin A and a synergistic effect of 5-FU on the growth of HT-29 cells was observed, and a COX-2 pathway for this effect was recognized; oroxylin A evidently elevated the level of reactive oxygen species in HT-29 cells, which subsequently inhibited COX-2 expression and enhanced the susceptibility of HT-29 cells to 5-FU.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	181-191	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	135-140
22607196-5	2012	Likely also related to COX-2 inhibition, oroxylin A decreased PGE(2) levels in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	41-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	23-28
22607196-6	2012	The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	BCL2 apoptosis regulator	Homo sapiens	90-95
22607196-6	2012	The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	tumor protein p53	Homo sapiens	121-124
22607196-6	2012	The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	BCL2 associated X, apoptosis regulator	Homo sapiens	126-129
22607196-6	2012	The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	collagen type XI alpha 2 chain	Homo sapiens	131-135
22607196-6	2012	The synergistic effect of 5-FU induced by oroxylin A was also found in the suppression of Bcl-2 and in the activation of P53, Bax, PARP, and procaspase-3 proteins in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	42-52	caspase 3	Homo sapiens	141-153
22607196-9	2012	This synergistic effect may be mainly related to COX-2 inhibition by oroxylin A in HT-29 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	69-79	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-54
22526619-0	2012	The role of Nrf2 and apoptotic signaling pathways in oroxylin A-mediated responses in HCT-116 colorectal adenocarcinoma cells and xenograft tumors.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	53-63	NFE2 like bZIP transcription factor 2	Homo sapiens	12-16
22560876-0	2012	Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	103-113	beclin 1	Homo sapiens	0-8
22560876-0	2012	Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	103-113	mechanistic target of rapamycin kinase	Homo sapiens	132-136
22560876-4	2012	We found for the first time that oroxylin A induced Beclin 1-mediated autophagy in human hepatocellular carcinoma HepG2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	beclin 1	Homo sapiens	52-60
22560876-6	2012	This induction was associated with the suppressing of PI3K-PTEN-Akt-mTOR signaling pathway by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	94-104	phosphatase and tensin homolog	Homo sapiens	59-63
22560876-6	2012	This induction was associated with the suppressing of PI3K-PTEN-Akt-mTOR signaling pathway by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	94-104	AKT serine/threonine kinase 1	Homo sapiens	64-67
22560876-6	2012	This induction was associated with the suppressing of PI3K-PTEN-Akt-mTOR signaling pathway by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	94-104	mechanistic target of rapamycin kinase	Homo sapiens	68-72
22560876-8	2012	It was further demonstrated that oroxylin A-triggered autophagy contributed to cell death using over-expression of autophagy-related gene (Atg5 and Atg7) and inhibition of autophagy by siBeclin 1 and 3-methyladenine (3-MA).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	autophagy related 5	Homo sapiens	139-143
22560876-8	2012	It was further demonstrated that oroxylin A-triggered autophagy contributed to cell death using over-expression of autophagy-related gene (Atg5 and Atg7) and inhibition of autophagy by siBeclin 1 and 3-methyladenine (3-MA).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	autophagy related 7	Homo sapiens	148-152
22609744-4	2012	In HepG2 but not L02 cells, oroxylin A induced substantial production of intracellular H2O2 and inordinate activation of the PERK-eIF2alpha-ATF4-CHOP branch of the unfolded protein response (UPR) pathway, which resulted in the induction of TRB3 and causal reduction of p-AKT1/2/3 (Ser473).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	125-129
22609744-4	2012	In HepG2 but not L02 cells, oroxylin A induced substantial production of intracellular H2O2 and inordinate activation of the PERK-eIF2alpha-ATF4-CHOP branch of the unfolded protein response (UPR) pathway, which resulted in the induction of TRB3 and causal reduction of p-AKT1/2/3 (Ser473).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	eukaryotic translation initiation factor 2A	Homo sapiens	130-139
22609744-4	2012	In HepG2 but not L02 cells, oroxylin A induced substantial production of intracellular H2O2 and inordinate activation of the PERK-eIF2alpha-ATF4-CHOP branch of the unfolded protein response (UPR) pathway, which resulted in the induction of TRB3 and causal reduction of p-AKT1/2/3 (Ser473).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	activating transcription factor 4	Homo sapiens	140-144
22609744-4	2012	In HepG2 but not L02 cells, oroxylin A induced substantial production of intracellular H2O2 and inordinate activation of the PERK-eIF2alpha-ATF4-CHOP branch of the unfolded protein response (UPR) pathway, which resulted in the induction of TRB3 and causal reduction of p-AKT1/2/3 (Ser473).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	DNA damage inducible transcript 3	Homo sapiens	145-149
22609744-4	2012	In HepG2 but not L02 cells, oroxylin A induced substantial production of intracellular H2O2 and inordinate activation of the PERK-eIF2alpha-ATF4-CHOP branch of the unfolded protein response (UPR) pathway, which resulted in the induction of TRB3 and causal reduction of p-AKT1/2/3 (Ser473).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	tribbles pseudokinase 3	Homo sapiens	240-244
22609744-6	2012	These results indicated that the H2O2-triggered overactivation of the UPR pathway and causal inactivation of AKT signaling contributed to the preferential cytotoxicity of oroxylin A in malignant HepG2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	171-181	AKT serine/threonine kinase 1	Homo sapiens	109-112
22526619-5	2012	We then found that both caspase-3 and caspase-9 were activated, the expression of Bcl-2 protein decreased, and the expression of Bax protein increased after treatment with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	172-182	caspase 3	Homo sapiens	24-33
22526619-5	2012	We then found that both caspase-3 and caspase-9 were activated, the expression of Bcl-2 protein decreased, and the expression of Bax protein increased after treatment with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	172-182	caspase 9	Homo sapiens	38-47
22526619-5	2012	We then found that both caspase-3 and caspase-9 were activated, the expression of Bcl-2 protein decreased, and the expression of Bax protein increased after treatment with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	172-182	BCL2 apoptosis regulator	Homo sapiens	82-87
22526619-5	2012	We then found that both caspase-3 and caspase-9 were activated, the expression of Bcl-2 protein decreased, and the expression of Bax protein increased after treatment with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	172-182	BCL2 associated X, apoptosis regulator	Homo sapiens	129-132
22526619-6	2012	In addition, oroxylin A increased nuclear transcription factor erythroid-related factor 2 (Nrf2) expression and induced Nrf2 translocation into the nucleus.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	NFE2 like bZIP transcription factor 2	Homo sapiens	34-89
22526619-6	2012	In addition, oroxylin A increased nuclear transcription factor erythroid-related factor 2 (Nrf2) expression and induced Nrf2 translocation into the nucleus.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	NFE2 like bZIP transcription factor 2	Homo sapiens	91-95
22526619-6	2012	In addition, oroxylin A increased nuclear transcription factor erythroid-related factor 2 (Nrf2) expression and induced Nrf2 translocation into the nucleus.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	NFE2 like bZIP transcription factor 2	Homo sapiens	120-124
22526619-7	2012	Furthermore, we found that oroxylin A treatment elevated intracellular reactive oxygen species levels and increased the protein expression level of two of the Nrf2 target genes heme oxygenase-1 and NADP(H):quinone oxidoreductase-1 in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	NFE2 like bZIP transcription factor 2	Homo sapiens	159-163
22526619-7	2012	Furthermore, we found that oroxylin A treatment elevated intracellular reactive oxygen species levels and increased the protein expression level of two of the Nrf2 target genes heme oxygenase-1 and NADP(H):quinone oxidoreductase-1 in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	heme oxygenase 1	Homo sapiens	177-193
22526619-9	2012	The in-vivo chemopreventive efficacy of oroxylin A against HCT-116 human colon cancer was accompanied by its proapoptotic and Nrf2-inducing activities, which correlates with the in-vitro study.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	NFE2 like bZIP transcription factor 2	Homo sapiens	126-130
22245252-0	2012	Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	TIMP metallopeptidase inhibitor 2	Homo sapiens	92-131
22366656-0	2012	Oroxylin A analogs exhibited strong inhibitory activities against iNOS-mediated nitric oxide (NO) production.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	nitric oxide synthase 2, inducible	Mus musculus	66-70
22366656-1	2012	A number of oroxylin A analogs were prepared and evaluated for their inhibitory activities against iNOS-mediated nitric oxide (NO) production from LPS-stimulated BV2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	nitric oxide synthase 2, inducible	Mus musculus	99-103
22245252-0	2012	Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen-activated protein kinase 3	Homo sapiens	152-158
22245252-4	2012	Moreover, oroxylin A led to the reduction of the activity and expression levels of MMP-2 and MMP-9 in gelatin zymography, real-time PCR and western blotting analysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	matrix metallopeptidase 2	Homo sapiens	83-88
22245252-4	2012	Moreover, oroxylin A led to the reduction of the activity and expression levels of MMP-2 and MMP-9 in gelatin zymography, real-time PCR and western blotting analysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	matrix metallopeptidase 9	Homo sapiens	93-98
23238475-9	2012	The results also indicated that oroxylin A could inhibit the expression of LPS acceptor toll-like receptor 4 (TLR4) and the activities of its downstream mitogen-activated protein kinases (MAPKs), including reducing expressions of the phosphorylation of JNK, p38, and ERK.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	toll-like receptor 4	Rattus norvegicus	110-114
24116271-0	2012	Oroxylin A Induces BDNF Expression on Cortical Neurons through Adenosine A2A Receptor Stimulation: A Possible Role in Neuroprotection.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	brain derived neurotrophic factor	Homo sapiens	19-23
24116271-0	2012	Oroxylin A Induces BDNF Expression on Cortical Neurons through Adenosine A2A Receptor Stimulation: A Possible Role in Neuroprotection.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	adenosine A2a receptor	Homo sapiens	63-85
24116271-5	2012	In this study, we investigated the possibility that oroxylin A modulates BDNF production in cortical neuron through the regulation of A2A receptor system.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	52-62	brain derived neurotrophic factor	Homo sapiens	73-77
24116271-6	2012	As ex-pected, CGS21680 (A2A receptor agonist) induced BDNF expression and release, however, an antagonist, ZM241385, prevented oroxylin A-induced increase in BDNF production.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	127-137	brain derived neurotrophic factor	Homo sapiens	158-162
24116271-7	2012	Oroxylin A activated the PI3K-Akt-GSK-3beta signaling pathway, which is inhibited by ZM241385 and the blockade of the signaling pathway abolished the increase in BDNF production.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	brain derived neurotrophic factor	Homo sapiens	162-166
24116271-8	2012	The physiological roles of oroxylin A-induced BDNF production were demonstrated by the increased neurite extension as well as synapse formation from neurons.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	brain derived neurotrophic factor	Homo sapiens	46-50
24116271-9	2012	Overall, oroxylin A might regulate BDNF production in cortical neuron through A2A receptor stimulation, which promotes cellular survival, synapse formation and neurite extension.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	brain derived neurotrophic factor	Homo sapiens	35-39
24116272-11	2012	Based on these findings, baicalin may be metabolized to baicalein and oroxylin A by intestinal microflora, which enhance its anti-inflammatory effect by inhibiting NF-kappaB activation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	70-80	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	164-173
23236370-0	2012	STAT1 mediates oroxylin a inhibition of iNOS and pro-inflammatory cytokines expression in microglial BV-2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	signal transducer and activator of transcription 1	Mus musculus	0-5
22310179-0	2012	Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinbeta1 and its related pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	integrin subunit beta 1	Homo sapiens	57-70
22310179-6	2012	The data corroborated that Integrinbeta1 played a significant role in CAM-DR. After the treatment of weakly-toxic concentrations of Oroxylin A, the apoptosis induced by Paclitaxel in the CAM-DR model increased dramatically.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	132-142	integrin subunit beta 1	Homo sapiens	27-40
22310179-7	2012	Western blot assay revealed Oroxylin A markedly down-regulated the expression of Integrinbeta1 and the activity of related pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	integrin subunit beta 1	Homo sapiens	81-94
22310179-8	2012	As a conclusion, Oroxylin A can reverse the resistance of CAM-DR via inhibition of Integrinbeta1 and its related pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	integrin subunit beta 1	Homo sapiens	83-96
22228220-0	2012	The molecular basis for the inhibition of human cytochrome P450 1A2 by oroxylin and wogonin.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	71-79	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	48-67
22228220-1	2012	In our previous kinetics studies the natural products oroxylin and wogonin were shown to have strong biological affinity for, and inhibitory effects against, human cytochrome P450 1A2, with IC(50) values of 579 and 248 nM, respectively; this might lead to the occurrence of drug-drug interactions when co-administered clinically.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	54-62	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	164-183
21557331-4	2012	Moreover, the mRNA and protein expression of multi-drug resistance gene (MDR1) were also decreased by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	102-112	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
21557331-5	2012	Further experiments exhibited that oroxylin A can downregulate P-gp expression through inhibiting nuclear factor-kappaB (NF-kappaB) signaling pathway, which might be the mechanism of reversal resistance of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	phosphoglycolate phosphatase	Homo sapiens	63-67
21557331-5	2012	Further experiments exhibited that oroxylin A can downregulate P-gp expression through inhibiting nuclear factor-kappaB (NF-kappaB) signaling pathway, which might be the mechanism of reversal resistance of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	206-216	phosphoglycolate phosphatase	Homo sapiens	63-67
21557331-6	2012	In summary, oroxylin A could be a good candidate for the development of new MDR reversal agent and its reversal mechanism probably due to the suppression of P-gp expression via inhibiting NF-kappaB signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	12-22	phosphoglycolate phosphatase	Homo sapiens	157-161
23236370-0	2012	STAT1 mediates oroxylin a inhibition of iNOS and pro-inflammatory cytokines expression in microglial BV-2 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	15-25	nitric oxide synthase 2, inducible	Mus musculus	40-44
23236370-8	2012	Our results indicated that oroxylin A (10-100 microM) in a concentration-dependent manner inhibited LPS-induced NO production via blocking iNOS expression at both mRNA and protein levels without affecting the degradation rate of iNOS mRNA.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	nitric oxide synthase 2, inducible	Mus musculus	139-143
23238475-9	2012	The results also indicated that oroxylin A could inhibit the expression of LPS acceptor toll-like receptor 4 (TLR4) and the activities of its downstream mitogen-activated protein kinases (MAPKs), including reducing expressions of the phosphorylation of JNK, p38, and ERK.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	mitogen activated protein kinase 14	Rattus norvegicus	258-261
23236370-8	2012	Our results indicated that oroxylin A (10-100 microM) in a concentration-dependent manner inhibited LPS-induced NO production via blocking iNOS expression at both mRNA and protein levels without affecting the degradation rate of iNOS mRNA.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	nitric oxide synthase 2, inducible	Mus musculus	229-233
23236370-9	2012	Moreover, oroxylin A significantly attenuated LPS-induced late expression (20 hours after LPS challenge) of IL-1beta and IL-6.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	interleukin 1 beta	Mus musculus	108-116
23236370-9	2012	Moreover, oroxylin A significantly attenuated LPS-induced late expression (20 hours after LPS challenge) of IL-1beta and IL-6.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	interleukin 6	Mus musculus	121-125
23236370-10	2012	Furthermore, oroxylin A significantly suppressed LPS-induced JAK2-mediated STAT1 phosphorylation without affecting LPS-induced NFkappaB-p65 nuclear translocation or NFkappaB-p65 DNA-binding activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	Janus kinase 2	Mus musculus	61-65
23236370-10	2012	Furthermore, oroxylin A significantly suppressed LPS-induced JAK2-mediated STAT1 phosphorylation without affecting LPS-induced NFkappaB-p65 nuclear translocation or NFkappaB-p65 DNA-binding activity.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	signal transducer and activator of transcription 1	Mus musculus	75-80
23238475-9	2012	The results also indicated that oroxylin A could inhibit the expression of LPS acceptor toll-like receptor 4 (TLR4) and the activities of its downstream mitogen-activated protein kinases (MAPKs), including reducing expressions of the phosphorylation of JNK, p38, and ERK.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	Eph receptor B1	Rattus norvegicus	267-270
23238475-11	2012	CONCLUSIONS: Taken together, oroxylin A can suppress the angiogenesis induced by LPS and it may affect the LPS/TLR4 signaling pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	29-39	toll-like receptor 4	Rattus norvegicus	111-115
21145362-10	2011	Increase in intracellular Ca(2+) concentration, phosphorylation of ERK1/2 and CREB, and BDNF expression by oroxylin A was blocked by NMDA receptor inhibitor MK-801 (10muM) as well as tetrodotoxin (TTX, 0.5 and 1muM).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	107-117	brain-derived neurotrophic factor	Rattus norvegicus	88-92
23236370-12	2012	These results suggest that oroxylin A, via suppressing STAT1 phosphorylation, inhibits LPS-induced expression of pro-inflammatory genes in BV-2 microglial cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	signal transducer and activator of transcription 1	Mus musculus	55-60
21145362-11	2011	The results from the present study suggest that the calcium and p-CREB dependent induction of BDNF expression, possibly via activation of synaptic NMDA receptor through the blockade of GABA(A) activity in cortical neuronal circuitry, might be responsible for the neuroprotective or memory enhancing effects of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	310-320	cAMP responsive element binding protein 1	Rattus norvegicus	66-70
21145362-11	2011	The results from the present study suggest that the calcium and p-CREB dependent induction of BDNF expression, possibly via activation of synaptic NMDA receptor through the blockade of GABA(A) activity in cortical neuronal circuitry, might be responsible for the neuroprotective or memory enhancing effects of oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	310-320	brain-derived neurotrophic factor	Rattus norvegicus	94-98
19888602-0	2010	Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	vascular endothelial growth factor A	Rattus norvegicus	50-84
21145362-0	2011	Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	brain-derived neurotrophic factor	Rattus norvegicus	21-25
21145362-0	2011	Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen activated protein kinase 3	Rattus norvegicus	54-58
21145362-0	2011	Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	cAMP responsive element binding protein 1	Rattus norvegicus	59-63
21145362-4	2011	In this study we determined whether oroxylin A modulates the level of brain derived neurotrophic factor (BDNF) in primary rat cortical neuronal culture, which is well known for its role on neuronal survival, neurogenesis, differentiation of neurons and synapses and learning and memory.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	brain-derived neurotrophic factor	Rattus norvegicus	70-103
21145362-4	2011	In this study we determined whether oroxylin A modulates the level of brain derived neurotrophic factor (BDNF) in primary rat cortical neuronal culture, which is well known for its role on neuronal survival, neurogenesis, differentiation of neurons and synapses and learning and memory.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	brain-derived neurotrophic factor	Rattus norvegicus	105-109
21145362-5	2011	Treatment of oroxylin A for 3-48h increased BDNF expression which was analyzed by ELISA assay and Western blot analysis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	brain-derived neurotrophic factor	Rattus norvegicus	44-48
21145362-6	2011	Oroxylin A induced slow but sustained increases in intracellular calcium level and activated ERK1/2 mitogen activated protein kinase (MAPK).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen activated protein kinase 3	Rattus norvegicus	93-99
21145362-6	2011	Oroxylin A induced slow but sustained increases in intracellular calcium level and activated ERK1/2 mitogen activated protein kinase (MAPK).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	mitogen activated protein kinase 3	Rattus norvegicus	134-138
21145362-7	2011	In addition, oroxylin A phosphorylated cyclic AMP response element binding protein (CREB) at Ser 133 in concentration and time dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cAMP responsive element binding protein 1	Rattus norvegicus	39-82
21145362-7	2011	In addition, oroxylin A phosphorylated cyclic AMP response element binding protein (CREB) at Ser 133 in concentration and time dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cAMP responsive element binding protein 1	Rattus norvegicus	84-88
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	mitogen activated protein kinase 3	Rattus norvegicus	22-26
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	mitogen activated protein kinase 3	Rattus norvegicus	83-89
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	cAMP responsive element binding protein 1	Rattus norvegicus	94-98
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	brain-derived neurotrophic factor	Rattus norvegicus	110-114
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	brain-derived neurotrophic factor	Rattus norvegicus	168-172
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	mitogen activated protein kinase 3	Rattus norvegicus	198-202
21145362-8	2011	Pretreatment with the MAPK inhibitor PD98059 (10muM) attenuated phosphorylation of ERK1/2 and CREB as well as BDNF production, which suggests that oroxylin A regulates BDNF production by activating MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	147-157	cAMP responsive element binding protein 1	Rattus norvegicus	203-207
21145362-9	2011	GABA(A) antagonist bicuculline mimicked the effects of oroxylin A on BDNF production as well as MAPK-CREB pathway.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	brain-derived neurotrophic factor	Rattus norvegicus	69-73
20411407-2	2010	The purposes of this study are to determine the UGT-isoform-specific metabolic fingerprint (or GSMF) of wogonin and oroxylin A, and to use isoform-specific metabolism rates and kinetics to determine and describe their glucuronidation behaviors in tissue microsomes.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	116-126	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	48-51
19888602-0	2010	Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	kinase insert domain receptor	Rattus norvegicus	93-96
19888602-0	2010	Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	kinase insert domain receptor	Rattus norvegicus	97-102
19888602-2	2010	METHODS: Transwell assay and tube formation assay were used to evaluate the effects of oroxylin A on vascular endothelial growth factor (VEGF)-induced migration and tube formation of human umbilical vein endothelial cells (HUVECs).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	87-97	vascular endothelial growth factor A	Rattus norvegicus	101-135
19888602-2	2010	METHODS: Transwell assay and tube formation assay were used to evaluate the effects of oroxylin A on vascular endothelial growth factor (VEGF)-induced migration and tube formation of human umbilical vein endothelial cells (HUVECs).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	87-97	vascular endothelial growth factor A	Homo sapiens	137-141
19888602-6	2010	RESULTS: Oroxylin A remarkably suppressed the VEGF-stimulated migration and tube formation of HUVECs.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	9-19	vascular endothelial growth factor A	Rattus norvegicus	46-50
19888602-9	2010	Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	vascular endothelial growth factor A	Rattus norvegicus	29-33
19888602-9	2010	Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	kinase insert domain receptor	Rattus norvegicus	61-64
19888602-9	2010	Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	kinase insert domain receptor	Rattus norvegicus	65-70
19888602-9	2010	Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	mitogen activated protein kinase 14	Rattus norvegicus	125-128
19888602-9	2010	Moreover, oroxylin A blocked VEGF-induced phosphorylation of KDR/Flk-1 and related downstream signaling molecules, including p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and Akt.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	AKT serine/threonine kinase 1	Rattus norvegicus	205-208
19585117-4	2010	The mRNA levels of thymidine synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) in HepG2 cells after oroxylin A and 5-FU combination treatment were observed by quantitative real-time PCR.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	108-118	dihydropyrimidine dehydrogenase	Homo sapiens	82-85
19585117-10	2010	Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	tumor protein p53	Homo sapiens	150-153
19585117-10	2010	Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	collagen type XI alpha 2 chain	Homo sapiens	166-170
19585117-10	2010	Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	234-239
19585117-10	2010	Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	BCL2 apoptosis regulator	Homo sapiens	241-246
19585117-10	2010	Western blotting assay revealed oroxylin A enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the expressions of apoptotic-inducing proteins P53 and cleaved PARP and decreasing the expression of apoptotic-inhibitory proteins COX-2, Bcl-2, and pro-caspase3.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	32-42	caspase 3	Homo sapiens	252-264
19626645-0	2009	Involvement of p53 in oroxylin A-induced apoptosis in cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	22-32	tumor protein p53	Homo sapiens	15-18
19626645-2	2009	In this study, we investigate whether p53 is involved in oroxylin A-triggered viability inhibition and apoptosis induction in cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	57-67	tumor protein p53	Homo sapiens	38-41
19626645-3	2009	In a panel of different cancer cell lines, more potent inhibitory effects of oroxylin A were observed in wtp53 cells than those in mtp53 or p53-null cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	77-87	tumor protein p53	Homo sapiens	107-110
19626645-4	2009	Moreover, p53-siRNA-transfected HepG2 cells showed lower levels of apoptosis induced by oroxylin A than control-siRNA-transfected cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	88-98	tumor protein p53	Homo sapiens	10-13
19626645-5	2009	Likewise, after oroxylin A treatment, p53-null K-562 cells displayed promoted apoptosis rate when transfected with wtp53 plasmid.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	16-26	tumor protein p53	Homo sapiens	38-41
19626645-6	2009	Western blot and real-time RT-PCR assay revealed that oroxylin A markedly upregulated p53 protein expression in HepG2 and p53-overexpressing K-562 cells, but had no influence on p53 mRNA synthesis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	54-64	tumor protein p53	Homo sapiens	86-89
19626645-6	2009	Western blot and real-time RT-PCR assay revealed that oroxylin A markedly upregulated p53 protein expression in HepG2 and p53-overexpressing K-562 cells, but had no influence on p53 mRNA synthesis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	54-64	tumor protein p53	Homo sapiens	122-125
19626645-6	2009	Western blot and real-time RT-PCR assay revealed that oroxylin A markedly upregulated p53 protein expression in HepG2 and p53-overexpressing K-562 cells, but had no influence on p53 mRNA synthesis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	54-64	tumor protein p53	Homo sapiens	122-125
19626645-7	2009	Furthermore, after co-treatment with cycloheximide, oroxylin A still exerted a little effect on p53 expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	52-62	tumor protein p53	Homo sapiens	96-99
19626645-10	2009	Additionally, the antioxidant N-acetyl-L-cysteine could obviously abrogate p53 stabilization triggered by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	106-116	tumor protein p53	Homo sapiens	75-78
19626645-11	2009	Therefore, it is summarized that oroxylin A stabilized p53 expression and induced apoptosis at the posttranslational level via downregulating MDM2 expression and interfering MDM2-modulated proteasome-related p53 degradation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	tumor protein p53	Homo sapiens	55-58
19626645-11	2009	Therefore, it is summarized that oroxylin A stabilized p53 expression and induced apoptosis at the posttranslational level via downregulating MDM2 expression and interfering MDM2-modulated proteasome-related p53 degradation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	MDM2 proto-oncogene	Homo sapiens	142-146
19626645-11	2009	Therefore, it is summarized that oroxylin A stabilized p53 expression and induced apoptosis at the posttranslational level via downregulating MDM2 expression and interfering MDM2-modulated proteasome-related p53 degradation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	MDM2 proto-oncogene	Homo sapiens	174-178
19626645-11	2009	Therefore, it is summarized that oroxylin A stabilized p53 expression and induced apoptosis at the posttranslational level via downregulating MDM2 expression and interfering MDM2-modulated proteasome-related p53 degradation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	33-43	tumor protein p53	Homo sapiens	208-211
19100732-0	2009	Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	matrix metallopeptidase 2	Homo sapiens	73-101
19739602-0	2009	Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	28-38	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
19739602-1	2009	Oroxylin A (1), a flavonoid from the roots of Scutellaria baicalensis, increased the cellular accumulation of calcein AM in a concentration-dependent manner in NCI/ADR-RES cells overexpressing P-glycoprotein over the concentration range 0-40 microM.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	193-207
19100732-7	2009	Oroxylin A also inhibited the expressions of MMP-2 and MMP-9 in MDA-MB-435 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	matrix metallopeptidase 2	Homo sapiens	45-50
19100732-7	2009	Oroxylin A also inhibited the expressions of MMP-2 and MMP-9 in MDA-MB-435 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	matrix metallopeptidase 9	Homo sapiens	55-60
19473757-7	2009	As Bax is an essential constituent of MAC in certain systems, we examined the activation, subcellular location, oligomeric structure of Bax in HepG2 cells treated with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	168-178	BCL2 associated X, apoptosis regulator	Homo sapiens	3-6
19473757-7	2009	As Bax is an essential constituent of MAC in certain systems, we examined the activation, subcellular location, oligomeric structure of Bax in HepG2 cells treated with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	168-178	BCL2 associated X, apoptosis regulator	Homo sapiens	136-139
19473757-8	2009	Moreover, our results showed that overexpression of Bcl-2 inhibited oroxylin A-induced apoptosis.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	68-78	BCL2 apoptosis regulator	Homo sapiens	52-57
19135124-6	2009	Then apoptosis induced by oroxylin A in HeLa cells was characterized by DAPI staining and Annexin V/PI double staining, and degradation of PARP (poly-ADP-ribose polymerase) was both found in HeLa cells and tumor tissue.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	annexin A5	Homo sapiens	90-99
19135124-6	2009	Then apoptosis induced by oroxylin A in HeLa cells was characterized by DAPI staining and Annexin V/PI double staining, and degradation of PARP (poly-ADP-ribose polymerase) was both found in HeLa cells and tumor tissue.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	26-36	poly(ADP-ribose) polymerase 1	Homo sapiens	139-143
19100732-8	2009	Additionally, oroxylin A exerted an inhibitory effect on the phosphorylation of extracellular regulated proteinkinases1/2 (ERK1/2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	mitogen-activated protein kinase 3	Homo sapiens	80-121
19100732-8	2009	Additionally, oroxylin A exerted an inhibitory effect on the phosphorylation of extracellular regulated proteinkinases1/2 (ERK1/2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	14-24	mitogen-activated protein kinase 3	Homo sapiens	123-129
19100732-4	2009	The results showed that oroxylin A suppressed MDA-MB-435 cell adhesion to the fibronectin-coated substrate in a concentration-dependent manner.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	24-34	fibronectin 1	Homo sapiens	78-89
19100732-6	2009	Zymography revealed that oroxylin A decreased the secretion of matrix metalloproteinases-2 (MMP-2) and metalloproteinases-9 (MMP-9).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	matrix metallopeptidase 2	Homo sapiens	63-90
19100732-6	2009	Zymography revealed that oroxylin A decreased the secretion of matrix metalloproteinases-2 (MMP-2) and metalloproteinases-9 (MMP-9).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	matrix metallopeptidase 2	Homo sapiens	92-97
19100732-6	2009	Zymography revealed that oroxylin A decreased the secretion of matrix metalloproteinases-2 (MMP-2) and metalloproteinases-9 (MMP-9).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	25-35	matrix metallopeptidase 9	Homo sapiens	125-130
17174385-7	2006	Histochemical and immunohistochemical studies showed that the number of Nissl bodies and OX-42 positive cells in the hippocampal CA1 and dentate gyrus regions were attenuated by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	178-188	carbonic anhydrase 1	Mus musculus	129-132
17069758-7	2006	The pro-apoptotic activity of oroxylin A was attributed to its ability to modulate the concerted expression of Bcl-2, Bax, and pro-caspase-3 proteins.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	30-40	BCL2 apoptosis regulator	Homo sapiens	111-116
17069758-7	2006	The pro-apoptotic activity of oroxylin A was attributed to its ability to modulate the concerted expression of Bcl-2, Bax, and pro-caspase-3 proteins.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	30-40	BCL2 associated X, apoptosis regulator	Homo sapiens	118-121
17069758-7	2006	The pro-apoptotic activity of oroxylin A was attributed to its ability to modulate the concerted expression of Bcl-2, Bax, and pro-caspase-3 proteins.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	30-40	caspase 3	Homo sapiens	127-140
17069758-8	2006	The expression of Bcl-2 protein and pro-caspase-3 protein was dramatically decreased after treatment with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	106-116	BCL2 apoptosis regulator	Homo sapiens	18-23
17069758-8	2006	The expression of Bcl-2 protein and pro-caspase-3 protein was dramatically decreased after treatment with oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	106-116	caspase 3	Homo sapiens	36-49
18957166-0	2008	Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	cyclin dependent kinase 7	Homo sapiens	63-67
18957166-0	2008	Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	cyclin dependent kinase 1	Homo sapiens	91-95
18957166-0	2008	Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	cyclin H	Homo sapiens	96-99
18957166-4	2008	Western blot analysis demonstrated that oroxylin A-induced cell-cycle arrest in BGC-823 cells was associated with a significant decrease in cdc2/p34, cyclin B1 and cyclin A expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	cyclin dependent kinase 1	Homo sapiens	140-144
18957166-4	2008	Western blot analysis demonstrated that oroxylin A-induced cell-cycle arrest in BGC-823 cells was associated with a significant decrease in cdc2/p34, cyclin B1 and cyclin A expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	cyclin H	Homo sapiens	145-148
18957166-4	2008	Western blot analysis demonstrated that oroxylin A-induced cell-cycle arrest in BGC-823 cells was associated with a significant decrease in cdc2/p34, cyclin B1 and cyclin A expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	cyclin B1	Homo sapiens	150-159
18957166-4	2008	Western blot analysis demonstrated that oroxylin A-induced cell-cycle arrest in BGC-823 cells was associated with a significant decrease in cdc2/p34, cyclin B1 and cyclin A expression.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	40-50	cyclin A2	Homo sapiens	164-172
18957166-5	2008	In addition, oroxylin A-treated cells decreased the expression of Cdk7, which was responsible for the low expression of M phase promoting factor (cyclin B1/Cdc2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cyclin dependent kinase 7	Homo sapiens	66-70
18957166-5	2008	In addition, oroxylin A-treated cells decreased the expression of Cdk7, which was responsible for the low expression of M phase promoting factor (cyclin B1/Cdc2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cyclin B1	Homo sapiens	146-155
18957166-5	2008	In addition, oroxylin A-treated cells decreased the expression of Cdk7, which was responsible for the low expression of M phase promoting factor (cyclin B1/Cdc2).	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	13-23	cyclin dependent kinase 1	Homo sapiens	156-160
18957166-6	2008	The results suggested that oroxylin A induced G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	cyclin dependent kinase 7	Homo sapiens	90-94
18957166-6	2008	The results suggested that oroxylin A induced G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	cyclin dependent kinase 1	Homo sapiens	118-122
18957166-6	2008	The results suggested that oroxylin A induced G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	cyclin H	Homo sapiens	123-126
17174385-8	2006	Moreover, phosphorylated cAMP response element-binding protein (CREB) and brain derived neurotrophic factor (BDNF) positive cell numbers were markedly increased in animals treated with oroxylin A than in untreated 2VO controls.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	185-195	cAMP responsive element binding protein 1	Mus musculus	25-62
17174385-8	2006	Moreover, phosphorylated cAMP response element-binding protein (CREB) and brain derived neurotrophic factor (BDNF) positive cell numbers were markedly increased in animals treated with oroxylin A than in untreated 2VO controls.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	185-195	cAMP responsive element binding protein 1	Mus musculus	64-68
17174385-8	2006	Moreover, phosphorylated cAMP response element-binding protein (CREB) and brain derived neurotrophic factor (BDNF) positive cell numbers were markedly increased in animals treated with oroxylin A than in untreated 2VO controls.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	185-195	brain derived neurotrophic factor	Mus musculus	74-107
17174385-8	2006	Moreover, phosphorylated cAMP response element-binding protein (CREB) and brain derived neurotrophic factor (BDNF) positive cell numbers were markedly increased in animals treated with oroxylin A than in untreated 2VO controls.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	185-195	brain derived neurotrophic factor	Mus musculus	109-113
17174385-9	2006	These results suggest that oroxylin A dramatically attenuates the memory impairment induced by 2VO, and that this effect may be mediated by the neuroprotective effects of oroxylin A as supported oroxylin A induced reductions in activated microglia and increases in BDNF expression and CREB phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	brain derived neurotrophic factor	Mus musculus	265-269
17174385-9	2006	These results suggest that oroxylin A dramatically attenuates the memory impairment induced by 2VO, and that this effect may be mediated by the neuroprotective effects of oroxylin A as supported oroxylin A induced reductions in activated microglia and increases in BDNF expression and CREB phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	27-37	cAMP responsive element binding protein 1	Mus musculus	285-289
17174385-9	2006	These results suggest that oroxylin A dramatically attenuates the memory impairment induced by 2VO, and that this effect may be mediated by the neuroprotective effects of oroxylin A as supported oroxylin A induced reductions in activated microglia and increases in BDNF expression and CREB phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	171-181	brain derived neurotrophic factor	Mus musculus	265-269
17174385-9	2006	These results suggest that oroxylin A dramatically attenuates the memory impairment induced by 2VO, and that this effect may be mediated by the neuroprotective effects of oroxylin A as supported oroxylin A induced reductions in activated microglia and increases in BDNF expression and CREB phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	171-181	cAMP responsive element binding protein 1	Mus musculus	285-289
17174385-9	2006	These results suggest that oroxylin A dramatically attenuates the memory impairment induced by 2VO, and that this effect may be mediated by the neuroprotective effects of oroxylin A as supported oroxylin A induced reductions in activated microglia and increases in BDNF expression and CREB phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	171-181	brain derived neurotrophic factor	Mus musculus	265-269
17174385-9	2006	These results suggest that oroxylin A dramatically attenuates the memory impairment induced by 2VO, and that this effect may be mediated by the neuroprotective effects of oroxylin A as supported oroxylin A induced reductions in activated microglia and increases in BDNF expression and CREB phosphorylation.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	171-181	cAMP responsive element binding protein 1	Mus musculus	285-289
11811938-6	2002	Saikogenin D and oroxylin A attenuated IL-6 production in LPS-stimulated alveolar macrophages of B6 more than in that of BALB.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	interleukin 6	Mus musculus	39-43
11936218-4	2002	Oroxylin A inhibited diclofenac 4-hydroxylation (CYP2C9) activity with a IC50 of 6.7 microM.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	49-55